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Abstract 
During the last two to three decades, a large body of work has revealed the 
molecular basis of many human disorders, including retinal and vitreoretinal 
degenerations and dysfunctions. Although belonging to the group of orphan diseases, 
they affect probably more than two million people worldwide. Most excitingly, 
treatment of a particular form of congenital retinal degeneration is now possible. A 
major advantage for treatment is the unique structure and accessibility of the eye and 
its different components, including the vitreous and retina. Knowledge of the many 
different eye diseases affecting retinal structure and function (night and color 
blindness, retinitis pigmentosa, cone and cone rod dystrophies, photoreceptor 
dysfunctions, as well as vitreoretinal traits) is critical for future therapeutic 
development. We have attempted to present a comprehensive picture of these 
disorders, including clinical, genetic and molecular information. The structural 
organization of the review leads the reader through non-syndromic and syndromic 
forms of (i) rod dominated diseases, (ii) cone dominated diseases, (iii) generalized 
retinal degenerations and (iv) vitreoretinal disorders, caused by mutations in more 
than 165 genes. Clinical variability and genetic heterogeneity have an important 
impact on genetic testing and counselling of affected families. As phenotypes do not 
always correlate with the respective genotypes, it is of utmost importance that 
clinicians, geneticists, counsellors, diagnostic laboratories and basic researchers 
understand the relationships between phenotypic manifestations and specific genes, 
as well as mutations and pathophysiologic mechanisms. We discuss future 
perspectives. 
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1.  Introduction 
 
Monogenic diseases of the retina and vitreous affect approximately 1 in 2000 
individuals, or more than 2 million people worldwide. Consequences for affected 
individuals are variable and can range from legal blindness in the most severe forms 
of retinal degenerations (Leber congenital amaurosis, LCA) to less severe or rather 
mild retinal dysfunctions (night blindness, achromatopsia). For most of them, no 
treatment can be offered. In the past 20-25 years, the knowledge about the molecular 
basis of retinal diseases has tremendously progressed and evidence for the 
contribution of genetic factors but also environmental circumstances is continuously 
accumulating. After a time period that was mainly characterized by the identification 
of genes and disease causing mutations for the monogenic retinal and vitreoretinal 
traits in families, we have now entered an era where not only monogenetic (classic 
Mendelian) but also multifactorial diseases are in the interest of clinical, genetic and 
basic research. Still, a reliable molecular diagnosis is possible for only half of the 
affected individuals or families with monogenic forms of retinal diseases. In addition, 
the predictive value of a mutation or risk allele for multifactorial disorders is 
problematic since the phenotypic and/or symptomatic consequences are highly 
variable. Nevertheless, the knowledge about the molecular mechanisms has also 
improved diagnostic assessment of patients by genetic testing. It is the ultimate goal 
to better understand the molecular etiology of these diseases and to develop 
approaches for therapeutic interventions. 
The diseases discussed in this article can be categorized in four major groups: (i) rod 
dominated diseases, (ii) cone dominated diseases, (iii) generalized retinal 
degenerations (affecting both photoreceptor cell types, rods and cones), and finally 
(iv) exudative as well as erosive vitreoretinopathies (Figure 1). Our disease 
classification also considers whether the ocular phenotype is associated with 
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pathologies of other tissues (syndromic forms) or only affects the retina, retinal 
pigment epithelium and the vireous body (non-syndromic forms). In addition, the 
mode of inheritance was used as one characteristic feature of the different disease 
phenotypes in order to categorize them. Our aim was to provide a comprehensive 
overview about the molecular basis of retinal and vitreoretinal diseases and to 
discuss selected aspects in more detail.  
 
2. Non-syndromic retinal and vitreoretinal diseases 
 
2.1 Diseases of rod photoreceptor cells (stationary and progressive) 
 
Rod photoreceptors represent the vast majority of light sensitive cells in the human 
retina. There are approximately 20 times more rods than cones. These cells are 
spezialized for low light intensities and are responsible for visual perception under 
dim light conditions. The center of the human retina, which contains the macula and 
fovea centralis, is devoid of rod photoreceptor cells but the flanking areas have the 
highest rod content, which decreases almost lineary towards the retinal periphery. 
The two major classes of stationary and progressive retinal diseases in humans are 
represented by different forms of stationary night blindness and retinitis pigmentosa, 
respectively. 
 
2.1.1 Congenital stationary night blindness / stationary rod diseases 
 
As the name implies, congenital stationary night blindness (CSNB) is a non-
progressive visual impairment present at birth. However, it is also one of the first 
symptoms in progressive diseases, including retinitis pigmentosa (RP). Therefore, a 
differential diagnosis by genetic testing can provide helpful and important information 
to the affected individuals and families, in order to exclude or confirm the clinical 
diagnosis and to provide counselling.  
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CSNB is heterogeneous in clinical and genetic terms. Currently, 11 genes are known 
to carry sequence alterations or mutations, which are associated with this disease 
(Figure 2, Table 1) (Audo et al., 2009; Bech-Hansen et al., 1998; Bech-Hansen et al., 
2000; Dryja et al., 1993; Dryja et al., 1996; Dryja et al., 2005; Fuchs et al., 1995; Gal 
et al., 1994; Li et al., 2009; Pusch et al., 2000; Strom et al., 1998; van Genderen et 
al., 2009; Wycisk et al., 2006; Yamamoto et al., 1997; Zeitz et al., 2005; Zeitz et al., 
2006). Mutations in these genes can be dominant, recessive or X-linked. With 
respect to clinical manifestations, several forms can be distinguished: Schubert 
Bornschein type of CSNB, the complete and the incomplete type of CSNB, and 
CSNB with fundus abnormalities. One of the most important diagnostic tools to 
discriminate the different clinical types is the electroretinogram (ERG), which 
measures the response of different retinal cell types to light. Schubert Bornschein 
CSNB shows a negative scotopic (dim light conditions) ERG, with normal a-wave 
(photoreceptor response) amplitude that is larger than that of the b-wave (bipolar cell 
and second order neuron response). Also, dark adaptation of rods is reduced 
drastically or even completely absent, while cone adaptation thresholds are variably 
elevated in most patients. There are two types of CSNB with regard to ERG 
characteristics: (i) the Riggs type with an absent rod and reduced cone response in 
the ERG and (ii) the Schubert Bornschein type with a so-called negative ERG under 
scotopic conditions. The Nougaret type of CSNB, which has been described in a 
large French family, is characterized by the Riggs type ERG and autosomal dominant 
inheritance. The disease was found to be due to mutations in the alpha subunit of 
transducin (Dryja et al., 1996). The Schubert Bornschein disease can be subdivided 
in (i) CSNB1 or complete CSNB and (ii) CSNB2 or incomplete CSNB. In CSNB1, the 
rod b-wave is significantly reduced or absent, while that of the cones is largely 
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normal. In the incomplete type of CSNB, both the rod and the cone b-wave 
amplitudes are reduced (Zeitz, 2007). 
The functional spectrum of genes involved in CSNB contains calcium channel 
subunits (CACNA1F, CACNA2D4, TRPM1), a calcium binding protein (CABP4), a 
metabotropic glutamate receptor (GRM6), but also molecules of the 
phototransduction cascade (GNAT1, GRK1, PDE6B, SAG, RHO) as well as proteins 
of unknown function (NYX). Interestingly, mutations in Rhodopsin and the beta 
subunit of the rod phosphodieasterase can lead to stationary and progressive retinal 
diseases. While most of the mutations in the RHO gene lead to autosomal dominant 
or recessive RP (see below), a few amino acid substitutions have been described 
which lead to stationary night blindness  (Figures 2 and 6) (al Jandal et al., 1999; 
Dryja et al., 1993; Rao et al., 1994; Sieving et al., 1995; Sieving et al., 2001; Zeitz et 
al., 2008). The respective mutations may lead to a constitutively active signal 
transduction at a relatively low level, which makes affected rod photoreceptor cells 
less sensitive to low light intensities. This has been shown for rhodopsin mutations 
(Sieving et al., 2001; Zeitz et al., 2008). The missense mutation c.884C>T 
(p.Ala295Val) in rhodopsin was found in a Swiss family with autosomal dominant 
CSNB. It was characterized in a functional assay, where the catalytic GTP exchange 
of transducin was measured. In the presence of 11-cis retinal, the respective mutant 
rhodopsin was found to be inactive, similar to wild-type. Contrary, in the absence of 
11-cis-retinal, unlike wild-type opsin, the mutant opsin constitutively activated 
transducin (Zeitz et al., 2008). Because of this constitutive activity, the affected 
individuals experience decreased sensitivity to light.   
In addition to this defect in rod photoreceptor cells themself, signal transmission 
between photoreceptors and the respective bipolar cells may be disturbed or even 
eliminated by mutations in different genes. The calcium channel subunits or the 
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metabotropic glutamate receptor mGluR6/GRM6 are interesting molecules to study 
and for understanding the complex interactions between photoreceptor and bipolar 
cells (Dryja et al., 2005; Zeitz et al., 2005). 
 
2.1.2 Retinitis pigmentosa and progressive rod cone diseases 
 
The term retinitis pigmentosa (RP) describes a group of clinically similar phenotypes 
associated with genetically heterogeneous causes. The disease onset and 
progression may vary significantly among patients, even within the same family. The 
patients frequently experience night blindness in the early phase of the disease, 
followed by loss of vision starting in the midperiphery and progressing towards the 
center which results in tunnel vision (Hamel, 2006). On the cellular level, these 
phenotypes correlate with a predominantly affected rod photoreceptor system. In 
later stages, the disease may further affect the cone photoreceptors eventually 
causing complete blindness. The diseased photoreceptors undergo apoptosis which 
is reflected in reduced outer nuclear layer thickness within the retina, as well as in 
lesions and/or retinal pigment deposits in the fundus. Patients may loose a significant 
portion of their photoreceptors before experiencing loss of visual acuity (Geller et al., 
1993). To assess the disease status and progression, electroretinographic 
measurements provide a sensitive method (Berson, 1993). In contrast to CSNB, 
which predominantly affects the b-wave, RP is characterized by reduced or absent a- 
and b-waves in the ERG. 
The prevalence of RP is estimated to be about one in 3500 individuals (Hartong et al., 
2006). After the first report about linkage of an RP locus to a DNA marker on human 
chromosome X twenty six years ago (Bhattacharya et al., 1984), over 40 genes have 
been  associated with RP (Figure 2, Table 2). Disease causing mutations may be 
inherited autosomal recessive (Abd El-Aziz et al., 2008; Banerjee et al., 1998; Bareil 
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et al., 2001; Collin et al., 2008; den Hollander et al., 1999; Dryja et al., 1995; Gal et 
al., 2000; Huang et al., 1995; Martinez-Mir et al., 1998; Maw et al., 1997; Maw et al., 
2000; McLaughlin et al., 1993; Morimura et al., 1998; Nakazawa et al., 1998; Rivolta 
et al., 2000; Thompson et al., 2001; Tuson et al., 2004; Zangerl et al., 2006; Zhang et 
al., 2007b) or dominant (Abid et al., 2006; Bowne et al., 2002; Chakarova et al., 2002; 
Chakarova et al., 2007; Farrar et al., 1991; Freund et al., 1997; Friedman et al., 2009; 
Kajiwara et al., 1991; Kajiwara et al., 1994; Keen et al., 2002; Kennan et al., 2002; 
McKie et al., 2001; Rebello et al., 2004; Sato et al., 2005; Vithana et al., 2001; Wada 
et al., 2001; Zhang et al., 2007a; Zhao et al., 2009), as well as X-linked (Meindl et al., 
1996; Roepman et al., 1996a; Roepman et al., 1996b; Schwahn et al., 1998). 
Interestingly, mutations in several genes can be either dominant or recessive (Bernal 
et al., 2008; Bessant et al., 1999; Coppieters et al., 2007; Davidson et al., 2009; 
Dryja et al., 1990; Morimura et al., 1999; Pierce et al., 1999; Sullivan et al., 1999). 
The majority of cases (50-60%) are autosomal recessive, sporadic or simplex 
(Hartong et al., 2006). Also, families with autosomal dominant (30-40%) and X-linked 
inheritance (5-20%) are frequently observed. Maternal (mitochondrial) inheritance is 
very rare in RP. 
 
The functions of the different RP-associated genes may be grouped into mainly five 
categories: (i) phototransduction, (ii) retinal metabolism, (iii) tissue development and 
maintenance, (iv) cellular structure, and (v) splicing. 
The splicing category will now be discussed in more detail. It is particularly interesting 
as it only contains genes that are widely expressed although the patients’ phenotype 
is restricted to photoreceptors in the retina. Around 10% of the RP-associated genes 
belong to this rather recently discovered category. The splicing-relevant gene 
products (PRPF3, PRPF8, PRPF31 and PAP1) are involved in the assembly of the 
9 
Berger et al., Manuscript for Progress in Retinal and Eye Research, (amended March 12 2010)
The molecular basis of human retinal and vitreoretinal diseases 
 
spliceosome, a basic component of the splicing machinery. The spliceosomal protein 
complex catalyzes the removal of intronic sequences from pre-mRNA transcripts. 
Since the removal of introns is essential for almost all transcripts of the cell, it is 
intriguing that mutations in genes of the splicing category exclusively result in RP. 
Possible explanations for this observation are: (1) Photoreceptors have specialized 
splicing machineries that make them more vulnerable to alterations in splice 
components than other cell types. (2) The splicing of photoreceptor-specific genes is 
selectively affected. (3) Due to specialized requirements (e.g. transcript turnover), 
photoreceptors depend more strongly than other cell types on efficient splicing. 
Studies first supported possible explanation 2 and suggested that the removal of 
intron 3 of RHO is inhibited by the mutated splice factor PRPF31 (Yuan et al., 2005). 
The authors expressed the mutated PRPF31 to detect the splice defect in RHO. 
Subsequently, studies suggested that haploinsufficiency is the underlying mechanism 
for PRPF31 mutations, i.e. the mutated allele is not expressed and the reduced gene 
dosage causes the disease (support for possible explanation 3) (Rio et al., 2008). 
Nevertheless, splicing of RPGR intron 9 has been found to be misregulated in 
patient-derived lymphoblastoid cell lines with PRPF31 mutations. In contrast, cell 
lines with PRPF8 mutations show more general splice defect of several transcripts 
(Ivings et al., 2008). The latter findings suggest that different disease mechanisms 
underly RP caused by mutations in different splice factor genes. 
 
Although the functional properties of several RP-associated genes have been 
extensively studied, genotype-phenotype correlations are incompletely understood. 
Frequently, they are complicated by multiple clinical features caused by mutations in 
the same gene (Figure 6). This observation often involves the complex molecular 
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properties of a single RP gene. Subsequently, examples will be discussed to 
illustrate the problems associated with genotype-phenotype correlations. 
RHO is among the most prominent RP-associated genes. RHO constitutes a 7-
transmembrane receptor protein which initiates the phototransduction cascade upon 
absorption of light by its chromophore 11-cis-retinal. The vast majority of mutations 
show a classical autosomal dominant inheritance leading to RP, the mechanism of 
which is fairly well understood as being either a gain-of-function or a dominant 
negative effect of the mutated protein (Mendes et al., 2005). Nevertheless, few 
mutations show an autosomal recessive inheritance or lead to night blindness only. 
Convincing models exist for RHO mutations associated with night blindness and 
have been discussed above. It is less clear why the missense mutation p.E150K in 
RHO was found to cause RP only in a homozygous state, whereas heterozygous 
carriers developed no RP phenotype. This is indicative of a recessive inheritance 
pattern (Kumaramanickavel et al., 1994). It is well possible that these recessive RHO 
mutations constitute exceptionally mild mutations that are either tolerated by the 
photoreceptor or lead to RP late in live (Neidhardt et al., 2006). The same may apply 
to night blindness-associated mutations. 
Overall, the progression of clinical symptoms in patients with RHO mutations seems 
milder compared to that in patients with RPGR mutations (Sandberg et al., 2007). 
The reason for this clinical variability is not understood. RPGR is the major X-linked 
recessive RP gene and is frequently associated with mutations in male patients. Male 
to male transmission of the phenotype does not occur. Nevertheless, families with 
dominant inheritance pattern, as well as patients showing other forms of retinal 
degenerations have been reported (Figures 2, 3 and 6) (Ayyagari et al., 2002; 
Demirci et al., 2002; Neidhardt et al., 2008). Also, there are a few examples of female 
carriers showing disease symptoms of variable degree (Banin et al., 2007; Li et al., 
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2005; Rozet et al., 2002). This effect might be attributed to a dominant nature of 
some of the mutations or non-random X-inactivation in the affected tissue, which has 
not been proven so far. An interesting feature of the RPGR gene is the generation of 
large numbers of splice variants (Kirschner et al., 1999; Kirschner et al., 2001). The 
alternative exon ORF15 of RPGR is expressed predominantly in retina and is a hot-
spot for RP-associated mutations (Vervoort et al., 2000). ORF15 transcripts give rise 
to several splice variants (Hong et al., 2002). Nevertheless, mutations in ORF15 are 
almost exclusively frameshift or stop mutations that cause premature termination 
codons. Thus this exon is likely to play a crucial role for the function of RPGR in the 
retina. Interestingly, mutations at the 3’ end of exon ORF15 tend to result 
predominantly in cone over rod dystrophies rather than RP (Ayyagari et al., 2002; 
Demirci et al., 2002; Moore et al., 2006; Ruddle et al., 2009; Shu et al., 2007; Walia 
et al., 2008; Yang et al., 2002). This indicates that functional properties of the 3’- or 
C-terminal RPGR region are relevant for the survival of cones. Furthermore, the 
existence of alternative splice variants affecting this part of the gene complicates a 
clear genotype-phenotype correlation, but indicates that transcript processing is 
involved in the underlying pathogenic process. We provided further support for the 
observation that RPGR splice variants are relevant for the function of cones and 
showed that RPGR isoforms containing the alternative exon 9a are predominantly 
expressed in cones of the human retina (Neidhardt et al., 2007). Since splicing is 
tightly regulated and its mis-regulation has previously been associated with several 
diseases (Faustino et al., 2003), even mild alterations of the patients’ splice pattern 
might give rise to modifications of the phenotype (Schmid et al., 2010). Consequently, 
up or down regulation of tissue-specific RPGR isoforms might be responsible for a 
shift between different clinical expressions like RP and COD and might further 
influence the phenotype in heterozygous mutation carriers.  
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Also in mice, the phenotype is variable and depends on the genetic background. We 
have generated mutant mouse lines with an in-frame deletion of exon 4 of the Rpgr 
gene (Brunner et al., 2009). This mutation was introduced in two different inbred 
mouse lines: either C57BL/6 or BALB/c. On the BL/6 background, the phenotype is 
rod dominated while it is predominantly affecting cones in the BALB/c line. 
Furthermore, mislocalization of rhodopsin and cone opsin is consistent with a 
function of Rpgr in transport mechanisms, as reported previously (Khanna et al., 
2005; Roepman et al., 2000). This functional property of Rpgr is also supported by 
our findings in transgenic mice with overexpression of the protein. We observed that 
male infertility was due to aberrant spermatozoa (Brunner et al., 2008). The 
associated flagellar phenotype was more severe in mice with a high copy number of 
the transgene compared to mice carrying less Rpgr copies. These findings further 
support a role of Rpgr in ciliary transport and show that it is not confined to the retina. 
This also explains why RPGR mutations in patients can lead to a syndromic 
phenotype. 
 
 
2.2 Cone and cone rod diseases (stationary and progressive) 
 
As mentioned above, the cone photoreceptor cells in the human retina are 
responsible for daylight vision and are instrumental for high visual acuity and colour 
discrimination. A recent review about the structure and evolution of the cone system 
summarizes our current knowledge about this class of photoreceptor cells (Mustafi et 
al., 2009). Only 5% of photoreceptor cells are cones. A human retina contains 
approximately 60 million rods and 3 million cones. The cone system has a high 
spatial resolution but is less sensitive to light as compared to rods. During evolution, 
primates have acquired trichromatic colour vision. Other mammals, including mice, 
are dichromatic. The three cone types (red, green and blue) in humans are 
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designated L, M, and S cones according to their sensitivity to photons. The L cones 
are most sensitive to low frequency photons (555-565 nm), the M cones to middle 
frequency photons (530-537 nm), and the S cones to supra frequency photons (415-
430 nm). There are twice as many L than M cones and the S cones constitute only 
5% of all cone photoreceptors. 
The cone photoreceptor cells are not evenly distributed in primate retinas. The 
macular region and its centre, the fovea centralis, contain almost exclusively cones, 
except S cones, which are located more peripherally. The gene NRL, which codes for 
a transcription factor, plays a crucial role during photoreceptor differentiation and 
promotes the rod development while it suppresses the cone programme. 
Human diseases that affect the cone system, such as macular or cone and cone rod 
degenerations, lead to severe visual impairment. Clinically, patients with these 
diseases have a decreased visual acuity, photophobia, nystagmus, and colour vision 
abnormalities. Night blindness occurs in later stages of the disease when the rod 
system also becomes affected. However, cone diseases can be stationary, e.g. the 
different forms of complete and incomplete achromatopsia. 
 
2.2.1 Stationary cone dysfunctions 
 
Stationary subtypes of cone dysfunctions are complete and incomplete 
achromatopsia. They are usually congenital. Affected individuals with complete 
achromatopsia show infantile nystagmus, poor visual acuity, photophobia and are 
unable to distinguish colours. Mutations in four genes can cause complete 
achromatopsia: CNGA3, CNGB3, GNAT2 and PDE6C (Figure 3, Table 1) (Chang et 
al., 2009; Kohl et al., 1998; Kohl et al., 2000; Kohl et al., 2002; Thiadens et al., 2009; 
Wissinger et al., 2001). GNAT2 codes for the cone-specific form of transducin, an 
essential component of the phototransduction cascade.  CNGA3 and CNGB3 code 
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for the alpha 3 and beta 3 subunits of the cyclic nucleotide gated chanel and are 
responsible for the ultimate step of the phototransduction cascade in cone 
photoreceptors that leads to membrane hyperpolarization when the channel is closed. 
PDE6C codes for the cone-specific alpha subunit of the cGMP phosphodiesterase. It 
plays a key role in the essential phototransduction cascade of cone photoreceptors 
and mutations were recently found in cone dysfunction diseases (Thiadens et al., 
2009). 
Patients with incomplete or atypical achromatopsia retain residual colour vision. Their 
visual acuity is mildly better compared to that of individuals with the complete form of 
the disease. All other symptoms are identical in both forms of the disease. Mutations 
in three autosomal genes (CNGA3, GNAT2 and PDE6C) have been associated with 
incomplete achromatopsia (Figure 3, Table 1). While the affore mentioned diseases 
affect all three cone types, there is one X-linked recessive stationary disease that 
affects the red and green opsin genes and consequently only two types of cones. 
The disease is designated blue cone monochromatism. This X-linked form of 
incomplete achromatopsia is associated with reduced visual acuity, nystagmus, and 
photophobia. The underlying gene defect involves the green (M) and the red (L) 
opsin genes on the human X chromosome (Nathans et al., 1986). Two disease 
mechanisms were proposed, which lead to a lack of functional opsin molecules: 
Either a loss of transcription caused by a deletion of the locus control region (LCR) 
upstream of the genes or the presence of a hybrid gene due to an unequal crossing 
over of the highly homologous red and green opsin genes. The latter reduces the 
number of tandemly arrayed opsin genes on the X chromosome to a single hybrid 
gene. 
Another stationary cone disease, designated oligocone trichromacy, presents with 
reduced visual acuity, mild photophobia, a reduced amplitude in the cone ERG but 
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normal colour vision (Andersen et al., 2009; Michaelides et al., 2004). A reduced 
number of foveal cones may be responsible for this disease. So far, mutations in the 
genes encoding the cone-specific transducin alpha subunit (GNAT2) and the beta 3 
subunit of the cyclic nucleotide gated channel (CNGB3) were associated with this 
form of cone dysfunction (Andersen et al., 2009; Rosenberg et al., 2004). 
 
 
2.2.2 Cone and cone rod dystrophies (CODs and CORDs) 
 
The age of onset for CODs or CORDs is usually during childhood or early adult life. 
The progressive cone diseases are generally more severe than the progressive rod 
dominated phenotypes (e.g. RP). Although some peripheral vision is preserved, it 
can lead to legal blindness earlier than RP. Affected individuals experience first 
symptoms of decreased visual acuity at school during the first decade of life. In 
addition, patients with progressive CODs and CORDs feel intense photophobia and 
variable degrees of colour vision abnormalities. Central scotomas can be also 
present upon visual field testing. The fundus examination frequently reveals pigment 
deposits and retinal atrophy in the macular region. To discriminate CORDs from 
CODs and macular degeneration, additional ophthalmologic examinations are 
needed (fluorescein angiography, fundus autofluorescence, ERG). In contrast to 
CODs, CORDs show a peripheral retinal involvement and the ERG is characterized 
by a decrease in both cone and rod responses. However, cone responses are more 
severely affected than the rod-specific ERG components. In pure CODs or early 
CORDs, scotopic ERG is normal.  In later disease stages, night blindness occurs and 
the loss of the peripheral visual field is progressing. This is different in rod dominated 
retinal diseases, where night blindness is one of the first symptoms and the disease 
progresses from the periphery to the centre. 
16 
Berger et al., Manuscript for Progress in Retinal and Eye Research, (amended March 12 2010)
The molecular basis of human retinal and vitreoretinal diseases 
 
Currently, about 20 different genes have been shown to carry mutations that cause 
non-syndromic progressive cone disease (Figure 3, Table 3). The mode of 
inheritance is either autosomal dominant, recessive, or X-linked.  
 
2.2.3  Macular degenerations (monogenic and AMD) 
The macula, a region of the retina with high density of cone photoreceptors, can 
undergo specific degenerative processes, called macular degeneration.  In this 
review, we discuss the classic monogenic forms of macular degeneration but also the 
multifactorial, age-related form of this disease.  
The heterogeneous clinical features of macular dystrophies include a progressive 
loss of visual acuity, colour vision abnormalities, and central scotomas. The disease 
can manifest early or late in life. The typical and very frequent age-related form of 
macular dystrophy is not a classic monogenic disease but involves a complex 
interaction of multiple genetic components and environmental factors.  
Patients with macular degenerations usually show a normal or only slightly reduced 
electrophysiologic response upon ERG and EOG testing. This is different to more 
generalized or severe cone as well as rod dominated diseases, which show a 
significant reduction of the a-wave amplitude in the scotopic ERG and can be used 
as a characteristic feature for differential diagnosis. Full field ERG is often normal, 
even if the patients are legally blind due to a macular degeneration. Application of a 
more sensitive method, multifocal ERG, allows measurements by recording 
electrophysiologic responses from hundreds of small retinal areas simultaneously 
within less than 10 minutes per eye (Marmor et al., 2003). With this method, 
scotomas of only a few millimeters in diameter can be identified and accurate 
quantification of the extent of retinal dysfunction is possible.  
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2.2.3.1 Monogenic macular dystrophies 
Monogenic macular dystrophies can occur as a part of a multiorgan disease (e.g. 
Alport syndrome, BBS, Refsum disease) or in non syndromic forms. The mode of 
inheritance can be dominant, recessive, or X-linked. However, most of the mutations 
show a dominant effect. Currently, more than 10 genes have been identified which 
carry pathogenic sequence variants in patients with macular degenerations  (Figure 3, 
Table 4a).  
Mutations in the ABCA4 gene, which encodes an ATP-binding cassette transporter, 
can lead to a variety of retinal degenerative diseases, including juvenile macular 
degeneration (Stargardt disease), RP, as well as cone or cone rod dystrophy 
(Allikmets et al., 1997; Briggs et al., 2001; Cremers et al., 1998; Fishman et al., 2003; 
Kitiratschky et al., 2008; Maugeri et al., 2000; Rozet et al., 1998). The combination of 
these different clinical entities has been observed even within a family (Klevering et 
al., 2004a). This might be due to the high frequency of ABCA4 mutation carriers in 
the general population (about 5%) (Maugeri et al., 1999). The ABCA4 gene encodes 
a membrane protein of the rod and cone photoreceptor outer segment disks (Sun et 
al., 1997). The gene consists of 50 exons and the open reading frame contains 2273 
amino acid residues. ABCA4 mutations may show variable expressivity of the 
phenotype. They can lead to COD, CORD, MD, or RP (Figures 2, 3 and 6, Tables 2, 
3, 4a and 4b). 
The variable expressivity of mutations in a single gene is also observed for peripherin 
(PRPH2) (Figures 2, 3 and 6, Tables 2, 3 and 4a). In the vast majority of cases, 
mutations are dominant and can lead to RP, pattern dystrophy, fundus flavimaculatus, 
vitelliform macular dystrophy, or cone rod dystrophy (Felbor et al., 1997; Kajiwara et 
al., 1991; Keen et al., 1994; Nakazawa et al., 1994; Weleber et al., 1993). PRPH2 
mutations were also shown to be responsible for digenic RP (Kajiwara et al., 1994). 
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This form of RP is caused by mutations in ROM1 and PRPH2 and only double 
heterozygotes develop disease symptoms. Variability of clinical manifestations of 
PRPH2 mutations was also observed within the same family (Apfelstedt-Sylla et al., 
1995).  
 
2.2.3.2 Age-related macular degeneration (AMD) 
As the name indicates, this form typically affects the elder population.  Not only age 
but also hypertension, smoking, diet, obesity and chronic inflammation have been 
discussed as environmental risk factors (Ambati et al., 2003).  Based on twin and 
family studies, convincing data have been collected that show a substantial 
contribution from genetic constitutions of the individual (reviewed by (Chamberlain et 
al., 2006; Patel et al., 2008)).   
AMD has a prevalence of 0.05% before the age of 50 years, which increases to 
about 12 % in a population older than 80 years of age. With a general tendency of an 
aging population, this condition of vision loss will cause an increasing amount of 
individual discomfort and associated costs (Augood et al., 2006; Javitt et al., 2003; 
Klaver et al., 2001). Ethnic barriers to attract the disease have not been described 
but differences in the severity of the clinical appearance are recognized.   
Several reviews provide different aspects of the progression in the field of AMD  
(Chamberlain et al., 2006; Edwards et al., 2007; Haddad et al., 2006; Lotery et al., 
2007; Patel et al., 2008; Scholl et al., 2007; Swaroop et al., 2007; Tuo et al., 2004).  
We would like to discuss here the genetic heterogeneity and its impact on the 
complexity of AMD.  The etiology of AMD differs from that of the monogenic forms of 
macular degenerations, which is also reflected by the fact that a combination of 
multiple genetic loci (Table 4b) but also environmental circumstances are responsible 
for the development of AMD (Patel et al., 2008; Scholl et al., 2007).  In the age-
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related form one can observe abnormalities of the retinal pigment epithelium (RPE) 
as well as the formation of characteristic deposits containing lipids and proteins, 
designated drusen. In general, two different types of AMD can be distinguished: (i) an 
exudative or wet form of AMD and (ii) a non-exudative or dry form. The latter can 
transform to an exudative form, which is found in about 15% of all patients.  In this 
form of AMD choroidal neovascularization (CNV) develops, which tends to cause 
vessel leakage and consequently bleeding occurs. The drusen can vary greatly in 
their position, number and size.  This phenotypic variability has contributed to the 
difficulties of recognizing a straight phenotype-genotype correlation. 
To identify genetic determinants involved in complex diseases, several approaches 
have been taken. The candidate gene approach has focused primarily on three 
aspects: (i) genes which had previously been identified in monogenic macular 
degenerations ; (ii) candidate genes which were chosen based on their function and 
(iii) genes within regions identified through linkage studies (Chamberlain et al., 2006; 
Patel et al., 2008; Scholl et al., 2007).  Due to limited access to large families and the 
uncertainty of a genetic model, association studies became more promising than 
linkage analyses, in particular with the availability of increased numbers of genetic 
markers (single nucleotide polymorphisms, SNPs) and therefore increased power of 
analysis, despite a small sample size.  In this review, we will focus on the 
understanding we have gained from studying candidate genes that can predispose to 
AMD.   
 
The role of the immune system in AMD 
The complement system is part of the innate defense mechanism. A large number of 
proteins (about 30) participate in a cascade reaction of which three different 
pathways have been described: the classical, the alternative and the lectin pathway.  
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The cascade can be inhibited by the complement factor H (CFH), a component of the 
alternative pathway. Uncontrolled activation of the system may lead to the formation 
of drusen (Sivaprasad et al., 2006). Histological analysis of the retina of AMD 
patients allowed the detection of many components of the complement system within 
these structures (Hageman et al., 2001).  Assessment of the frequency of the 
p.Y402H variant, (c.1277T> C)  (SNP rs1061170) of CFH in AMD patients compared 
to control populations allowed the identification of the first risk locus (odds ratios 
ranging between 4.54 and  11.61 in homozygous individuals) (Edwards et al., 2005; 
Haines et al., 2005; Klein et al., 2005; Zareparsi et al., 2005).  Individuals that carry 
the histidine variant at position 402 of the protein are at approximately 50% risk to 
develop AMD, either the form of geographic atrophy or the exudative, neovascular 
form (Patel et al., 2008). Accordingly, non-carriers may experience protection against 
AMD. Environmental risks, such as smoking and body mass index, do not appear to 
increase the risk in combination with the CFH sequence variants (Lotery et al., 2007). 
In contrast, ethnic origin was reported to have a modifying effect (Lotery et al., 2007).  
Since amino acid position 402 lies within a region of CFH that interacts with heparin 
and C-reactive protein (CRP) (Giannakis et al., 2003) it was suggested that altered 
binding to these components on the outer retinal surface could affect the level of 
inflammation and consequently affect the development of AMD (Edwards et al., 2005; 
Haines et al., 2005; Klein et al., 2005).  Spurred by this initial report, several other 
studies confirmed the association of CFH with AMD.  A meta-analysis indicated a 
multiplicative genetic model with each risk allele increasing the odds of AMD by 
approximately 2.5 fold (Thakkinstian et al., 2006).   
While the CFH p.Y402H variant is associated with AMD in Caucasian (Conley et al., 
2005; Hageman et al., 2005; Kim et al., 2008; Maller et al., 2006; Narayanan et al., 
2007; Scholl et al., 2008; Seddon et al., 2009; Zareparsi et al., 2005) and Chinese 
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populations (Lau et al., 2006), it was not found in Japanese patients with exudative 
AMD (Gotoh et al., 2006).  Several factors may explain population differences: first, 
different allele frequencies (the C allele frequency is 0.282 in Caucasian population 
(HAP-MAP CEU) and 0.057 in Japanese population (HAP-MAP JPT); Ref: NCBI May 
2008); second, the prevalence of late stage AMD is higher in Caucasians compared 
to Japanese population (Oshima et al., 2001) and third, formation of drusen is less 
frequent in Japanese patients (Bird, 2003).  Interestingly, the C allele is significantly 
associated with the risk for AMD (odds ratio of 4.4) in the Han-Chinese (Beijing) 
population, despite its only slightly higher frequency (frequency: 0.067) (Lau et al., 
2006).  Whether the C-allele is associated with both forms of advanced AMD in the 
Chinese population is not yet clear since only the neovascular form of AMD was 
tested.   
Complement factors CFB, C2 , C3 and C5 are further components involved in the 
activation of the alternative pathway.  CFB and C3 products were shown to 
accumulate in drusen and Bruch’s membrane of AMD patients and genetic variants 
for CFB and C2 confer increased risk (Odds ratio of 1.32) as well as protection (Odds 
ratio 0.36 and 0.45) (Gold et al., 2006). These data have been confirmed in a 
replication study (Spencer et al., 2007).  By conferring reduced hemolytic activity, the 
p.R32Q variant of CFB could contribute to the protective function (Gold et al., 2006; 
Spencer et al., 2007). Furthermore, the absence of CFH-related genes CFHR1 and 
CFHR3 is also associated with protection against AMD (Hughes et al., 2006). While 
no association was found with variants in the C5 locus, the non-synonymous change 
p.R102G in C3 was associated with both, the dry and wet form of AMD ( GR/RR: 
odds ratio 1.61; GG/RR odds ratio 3.26) (Maller et al., 2007).  This association was 
independently confirmed in another Caucasian population (Spencer et al., 2008).  
The possibility of interaction between the C3, CHF, CFB and C2 components could 
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not be confirmed (Maller et al., 2007).  Since complement C1 activates components 
C2 and C4, inhibition of C1 leads to alteration of the complement cascade.  DNA 
sequence variants in the SERPING1 gene, which codes for the serine protease 
family member serpin peptidase inhibitor, clad G, confer a protective effect on AMD, 
regardless whether patients are affected by choroidal neovascularization (CNV) or 
geographic atrophy (GA) (Ennis et al., 2008).  Failure to replicate these findings in a 
different patient cohort (Park et al., 2009) may reflect a cohort-specific effect.   
Taken together, convincing evidence has been presented over the last four years 
showing that sequence alterations in components of the complement cascade 
contribute significant effects on the risk to develop AMD.  Sequence variants in some 
of them might provide protection against AMD development.   
Perturbation of the signaling cascade leading to inflammation has also been 
proposed to cause susceptibility to AMD (Ambati et al., 2003; Donoso et al., 2006). 
Within this context, the G allele (c.1063A>G) of the toll-like receptor 4 (TRL4), a 
bacterial endotoxin receptor, increases the risk of developing either the dry or wet 
form of AMD  within a Causasian population (odds ratio around 2.65) (Zareparsi et al., 
2005).  In addition, TRL4 participates in the phagocytosis of photoreceptors, a 
process which is important during the normal visual cycle and if perturbed, may lead 
to AMD.  Another Toll-like receptor gene, TRL3, which encodes a viral sensor that 
supports the innate immune defense system could be associated with protective 
function of a coding variant in AMD with geographic atrophy (odds ratio for the T 
allele at SNP rs3775291 ranged between 0.198 and 0.712) but not with the 
neovascular or early form (Yang et al., 2008b).  Whether double stranded viral RNA, 
the substrate for TRL3, does in fact exist in the eye, remains to be investigated.  In 
general, Yang and colleagues propose that this protective effect may be due to 
suppression of RPE cell death.  In an earlier study Edwards and colleagues reported 
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only marginal association of variants in TRL3, TRL4 and TRL7 with AMD (Edwards et 
al., 2008). It is noteworthy, that the number of patients with geographic atrophy was 
relatively small (16% of 396 AMD patients) and may have diluted the association 
results for the dry form of AMD.   
 
The role of the stress response in AMD 
A link between the immune response contributing to AMD and oxidative stress 
damage was proposed from studies in mice (Hollyfield et al., 2008).  It was 
hypothesized that Increased oxidative stress may lead to an increase in modified 
low-density lipoprotein, which in turn can be inhibited by paraoxonase (Mackness et 
al., 1993).  This enzyme is encoded by the gene PON1, of which two variants in the 
protein coding sequence of the gene were shown to be associated with AMD in a 
Japanese population (Chi square: 6.226 and 6.863 with P=0.445 and 0.323, for the 
two variants respectively) (Ikeda et al., 2001).  The attempt to replicate these findings 
in a patient cohort from Australia failed (Baird et al., 2004).  Different allele 
frequencies together with differences in the AMD phenotype between these 
populations might be the reason (Bird, 2003; Oshima et al., 2001).    
Another stress response protein, serine pronase encoded by the HTRA1 gene on 
chromosome 10q26, is expressed in the retina and the RPE and found at elevated 
levels in drusen (Yang et al., 2006).  HTRA1 is involved in the regulation of 
degradation of extracellular matrix proteoglycans and binds to transforming growth 
factor beta, which in turn regulates extracellular matrix deposition and angiogenesis 
(Oka et al., 2004).   Lotery and Trump speculated that overexpression may alter the 
integrity of Bruch’s membrane, allowing the invasion of vasculature (Lotery et al., 
2007).  These features and its location to a previously mapped risk region on 
chromosome 10 made HTRA1 a candidate for conferring an effect on the likelihood 
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to develop AMD, and in fact sequence variant rs11200638 in the promoter of HTRA1  
confers a risk for AMD in Caucasian and Chinese populations. The SNP rs10490924 
in the nearby ARMS2 (LOC387715) locus is also associated with an increased risk 
for AMD. Since the two loci are in tight linkage disequilibrium it is difficult to 
determine the relative contribution for each variant (odds ratios range between 2.7 
and 11.14) (Dewan et al., 2006; Jakobsdottir et al., 2005; Rivera et al., 2005; Weger 
et al., 2007; Yang et al., 2006). Recently, an insertion/deletion polymorphism near 
the 3’end of the ARMS2(LOC387715) locus was found to affect polyadenylation of its 
transcript (Fritsche et al., 2008).  ARMS2 encodes a mitochondrial protein that 
localizes to the ellipsoid region of the photoreceptors and may as such confer risk to 
develop AMD (Fritsche et al., 2008).  Furthermore, microsomal glutathione-S-
transferase 1 (MGST-1) is part of the oxidative stress pathways and was implicated 
to play a role in AMD (Maeda et al., 2005) but no association with AMD was found 
(Haines et al., 2006).    
 
Vasculogenesis and angiogenesis 
The exudative form of advanced AMD is characterized by neovascularization and 
hence it seems reasonable to search for genes that are involved in this process and 
may carry variants which influence the development of wet AMD (Grisanti et al., 
2008). Vascular endothelial growth factor (VEGF) encodes a homodimeric glycol 
protein, specifically produced by endothelial cells.  It is a critical regulator of 
vasculogenesis and angiogenesis and involved in the induction of permeability of 
blood vessels. In addition VEGF is also required for normal maintenance of the 
vasculature.  Among the different members of the VEGF gene family, VEGF-A is the 
most abundantly expressed and its nine different isoform are a result of differential 
splicing.  The VEGF-A 120 variant is the target of treatment with anti-VEGF 
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antibodies (Macugen, Ranibizumab (Lucentis) and Bevacizumad (Avastin) of patients 
with the wet/exudative form of AMD (Pieramici et al., 2008). Hypoxic conditions 
(Fruttiger, 2007) as well as an imbalance of angiogenic and anti-angiogenic factors 
(an example is pigment epithelium derived growth factor (PEDF)) can lead to retinal 
or choroidal neovascularization (Bhutto et al., 2006).  In a family-based and a case 
control data set, DNA variants in VEGFA were shown to be associated with AMD 
(Haines et al., 2006).  In addition, a haplotype including nine DNA sequence variants 
in the promoter of VEGFA also associates strongly with neovascular AMD within a 
population of northern European origin (odds ratio of 18.24) (Churchill et al., 2006).  
Furthermore, association was also found in an AMD patient population from Taiwan 
with a sequence variant in the 3’UTR of VEGFA (Lin et al., 2008).  Other attempts to 
replicate association with VEGFA have failed, including the Rotterdam study 
(Boekhoorn et al., 2008; Richardson et al., 2007). Heterogeneity in the patient 
populations could account for these inconsistent findings. Nevertheless, further 
investigations are required to fully understand the complexity of VEGFA involvement 
in the exudative form of AMD.   
 
In summary, the search for susceptibility loci has contributed a substancial number of 
genes implicated in contributing to the risk of developing AMD but also with 
protective effects.  As approximately half of the number of genes studied yield 
conflicting findings (Table 1 in reference Lotery and Trump (Lotery et al., 2007) 
further components influencing AMD remain to be identified.   
 
2.3 Generalized photoreceptor diseases (non-syndromic) 
 
2.3.1 Leber congenital amaurosis (LCA) 
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The retinal dystrophy designated Leber congenital amaurosis (LCA) is the most 
severe in terms of visual loss and has a very early age of onset (<1 year of age). The 
clinical features include congenital or early onset loss of vision, sensory nystagmus 
and no light response upon electrophysiology (ERG). The frequency of the disease is 
about 1 in 50000. The genetic heterogeneity of this disease is considerable. 
Currently, 15 genes were identified to carry mutations in patients affected by this 
disease (Figure 4, Table 5). The mode of inheritance of most of the mutations is 
autosomal recessive. Dominant inheritance is discussed for sequence alterations in 
CRX and IMPDH1. Functionally, the different gene products are involved in many 
cellular functions including photoreceptor development and differentiation, 
phototransduction, vitamin A metabolism and others. Recently, a review has been 
published which summarizes clinical, genetic, diagnostic and also functional details 
about this group of diseases (den Hollander et al., 2008). Because of the recessive 
nature of most mutations, genetic homozygosity mapping is a particularly successful 
approach in order to identify the underlying molecular basis of the disease within 
families.  
One of the genes which is associated with LCA was designated RPE65 (Marlhens et 
al., 1997). It encodes a protein consisting of 533 amino acid residues with high 
abundance in the retinal pigment epithelium. The protein is an isomerase and 
involved in the conversion of all-trans retinol to 11-cis retinal. Gene transfer of the 
RPE65 gene in the eyes of patients provides the first example for a successful gene 
therapy in human patient with this severe form of retinal dystropohy (Bainbridge et al., 
2008; Hauswirth et al., 2008; Maguire et al., 2008), which is further described below. 
 
2.3.2 Choroideremia 
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Choroideremia (CHM) is an X-linked inherited retinal degeneration with an estimated 
incidence rate of 1: 50,000.  Symptoms begin with night blindness during teenage 
years and the disease progressively affects degeneration of photoreceptor cells, 
retinal pigment epithelial cells, the choriocapillaris and the choroid, leading to 
complete blindness.  This disease is caused by mutations in the REP1 gene 
(Cremers et al., 1990; Merry et al., 1992), which encodes Rab escort protein-1.  It 
mediates prenylation of Rab GTPases and affects their involvement in intracellular 
vesicular transport (Preising et al., 2004; Seabra et al., 1993).  Among the numerous 
reported mutations (McTaggart et al., 2002), which cause frameshift, nonsense or 
splice site alterations, no missense mutations have been found.  In contrast to 
mutations that affect only the REP1 locus leading to non-syndromic CHM, large gene 
deletions are known to cause syndromic phenotypes ((Poloschek et al., 2008) and 
references therein). Although the gene is ubiquitously expressed, mutations affect 
primarily retinal structures (Seabra et al., 2002).  Expression of REP2 can 
compensate for the loss of functional REP1, except in the ocular structures, which 
leads to the specific eye phenotype (Cremers et al., 1994).  This hypothesis is 
supported by the recent finding that nonmammalian vertebrates do not have the 
REP2 gene and hence REP1 mutations are lethal (Moosajee et al., 2009). The 
disease-causing mechanism is still unclear but two models are discussed: a cascade 
type effect on the three layers photoreceptors, RPE and choroids, or an independent 
degeneration of them (Tolmachova et al., 2006). 
 
2.3.3 Gyrate atrophy of the choroid and retina 
Gyrate atrophy or ornithine aminotransferase deficiency, a slowly progressive 
chorioretinal degeneration, is inherited in an autosomal recessive pattern. The ocular 
symptoms include night blindness, myopia and a progressive loss of peripheral vision 
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in the first decade of life, posterior subcapsular cataracts in the second and blindness 
in the fourth to fifth decade. There might be a mild skeletal muscle weakness and 
mental retardation but these extraocular symptoms are present only occasionally. An 
arginine restricted diet (arginine is the precursor of ornithine) has been described to 
be beneficial in some patients. However, the slow progression of the disease makes 
it difficult to quantify the effect of treatment. The disease is caused by mutations in 
the ornithine aminotransferase gene (OAT) on human chromosome 10 (Valle et al., 
1977). The disorder appears to be very rare with a higher incidence in Finnland (1 
affected individual in 50000). The first mutation in this gene has been reported more 
than twenty two years ago (Mitchell et al., 1988). 
 
2.4 Vitreoretinopathies 
 
2.4.1 Erosive vitreoretinopathies 
 
This group of rare diseases encompasses pathological appearance of the vitreous 
associated with retinal changes that may include the retinal pigment epithelium.  We 
count several hereditary diseases to this group which are traditionally known as 
Stickler syndrome, snowflake vitreoretinal degeneration, Goldmann-Favre syndrome, 
autosomal dominant vitreoretinochoroidopathy (ADVIRC), Wagner syndrome and 
erosive vitreoretinopathy (ERVR) (Figure 5, Table 6).  Due to most recent molecular 
data, the latter two are now known as VCAN-related vitreoretinopathies (reviewed in 
(Kloeckener-Gruissem et al., 2009).  Vitreous syneresis, retinal changes with retinal 
detachment, development of cataract, poor night vision, visual field defects and 
abnormal ERG recordings, all of progressive nature, are clinical characteristics of 
these vitreoretinopathies. In most patients, first signs become obvious during the late 
teenage years. Restriction of visual acuity is among the first complaints of the 
patients.  The affected vitreous is frequently described as “empty” with veils and 
29 
Berger et al., Manuscript for Progress in Retinal and Eye Research, (amended March 12 2010)
The molecular basis of human retinal and vitreoretinal diseases 
 
strands. Except in autosomal dominant vitreoretinochoroidopathy, retinal detachment 
is a common accompanying feature of the phenotype. Clinically, the type of retinal 
detachment frequently allows the distinction between the different vitreoretinopathies.  
While tractional detachment is the more typical type in Wagner disease and erosive 
vitreoretinopathy, the rhegmatogenous type of retinal detachment is characteristic for 
Stickler syndrome and Snowflake vitreoretinal degeneration.  In the following 
sections we aim to discuss the specific phenotypes with their underlying molecular 
basis.   
 
Enhanced S-cone syndrome (ESCS)  
ESCS patients show the rather unusual effect of gain of function of photoreceptors 
with varying degrees of severity of retinal degeneration.  The more severe type is 
also known as Goldmann Favre syndrome (GFS).  A liquefied vitreous body with 
preretinal band-shaped structures, development of cataract, macular changes like 
retinoschisis, pigment loss and a severely affected electroretinogram belong to the 
typical clinical picture in GFS patients.  The retina displays areas with thickened 
layers localized to an annulus encircling the central fovea (Jacobson et al., 2004).  
The patients have severely reduced numbers of rods and L and M type cone 
photoreceptors but simultaneously they show an increased numer of S cone 
photoreceptors (Milam et al., 2002). The molecular cause for this is most likely 
related to recessive mutations in the nuclear receptor gene NR2E3, which encodes a 
transcription factor whose expression pattern appears to be restricted to the outer 
nuclear layer of the adult retina (Haider et al., 2000). Either single nucleotide 
substitutions, in particular the R311Q substitution, or small deletions affecting the 
coding region lead to an altered function of the transcription factor (Milam et al., 
2002).  Patients carry either homozygous mutations or are compound heterozygous 
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(Lam et al., 2007).  Interestingly, all mutations map to evolutionary conserved protein 
domains (Haider et al., 2000).  Probably, mutations in NR2E3 cause abnormal cell 
fate during development of the retina, leading to an excess of S-cones at the 
expense of rods and L and M cones.  In addition, a donor retina from a patient 
carrying the R311Q mutation displayed severe structural disorganization such that 
the cones were densely packed and interspersed with inner retinal neurons (Milam et 
al., 2002).  It remains subject to speculation how mutations in NR2E3 relate to the 
vitreous syneresis typically found in GFS.     
 
Snowflake vitreoretinal degeneration  
The pattern of inheritance of this disease is also autosomal dominant.  Patients show 
early onset cataract, vitreoretinal dystrophy, fibrillar degeneration of the vitreous and 
peripheral retinal abnormalities including shiny crystalline-like deposits resembling 
snowflakes.  Rhegmatogenous retinal detachment is observed. The first family with 
snowflake vitreoretinal degeneration was originally described by Hirose et al (Hirose 
et al., 1974) with a follow up description (Lee et al., 2003). Using DNA from affected 
and unaffected members of this family a mutated nucleotide (c.484C>T, p.R162W) of 
the gene KCNJ13 on chromosome 2 was found to segregate with the phenotype.  
KCNJ13 encodes Kir7.1, member 13 of subfamily J of the potassium inwardly 
rectifying channel family (Hejtmancik et al., 2008). Transcript analysis of KCNJ13 
demonstrated expression in kidney and brain and within the eye in adult and neural 
retina and RPE cells (Yang et al., 2008a). The mutation (484C>T, R162W) disrupts 
the structure of the channel, which is the most likely cause for the retinal phenotype.  
Understanding the vitreous phenotype remains a challenge since the channel has not 
been shown to be a structural part of the vitreous (Hejtmancik et al., 2008).    
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Autosomal dominant vitreoretinochoroidopathy (ADVIRC)  
This rare disease was first described by Kaufmann et al. (Kaufmann et al., 1982).  
Characteristic fibrillar condensation within the vitreous is not accompanied by the 
appearance of an optically “empty” vitreous, as described in patients with Wagner 
syndrome. Furthermore, retinal breaks, retinal detachment, systemic or skeletal 
abnormalities are also missing. Typical to this dease are the following features: a 
hyperpigmented band of cells at the peripheral retina which is punctuated with white 
opacities, the breakdown of the blood retinal barrier with retinal neovascularization, 
presenile cataract and occasionally choroidal atrophy.  Disease progression is very 
slow (Kaufmann et al., 1982) but can be recognized by ERG measurements since 
younger patients display a normal pattern that becomes moderately abnormal later in 
life. Rod photoreceptor cells seemed more severely affected than cones (decreased 
amplitude of a- and b-wave).  An abnormal electro oculogram suggested a defect at 
the level of the RPE.  Mutations in the gene VMD2, which is expressed in the RPE, 
were found to cause ADVIRC (Yardley et al., 2004). VMD2 encodes bestrophin, a 
trans-membrane protein expressed in the RPE.  It was first found to be involved in 
Best disease (vitelliform macular dystrophy, which is described elsewhere in this 
review). All VMD2 mutations are exonic and were found to cluster, irrespective of the 
different diseases, to regions in the trans-membrane domains (Table 7).   
 
Table 7: Neighboring VMD2 mutations cause different disease phenotypes. 
Mutation Protein Disease Effect 
c.253T>C p.Y85H Best disease no effect on splicing 
c.256G>A p.V86M ADVIRC novel splice variants 
 p.V89A Best disease  
 p.V235L Best disease  
 p.V235M Best disease  
c.707A>G p.Y236C ADVIRC novel splice variants 
 p.T237R Best disease  
c.715G>A p.V239M ADVIRC novel splice variants 
c.727G>A p.T241N Best disease no effect on splicing 
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To explain how the closely spaced missense mutations can result in these two 
different phenotypes, Yardly et al. hypothesized that splicing might be affected via 
exonic splicing regulatory elements (Yardley et al., 2004).  This hypothesis could be 
verified by using an in vitro mini gene functional assay.  Production of novel splice 
variants was specific only for those mutations causing ADVIRC, but not for the 
neighboring Best disease causing mutations.  With this high degree of genotype-
phenotype correlation the authors suggest that the abnormal splice products have a 
novel effect on ocular development (Yardley et al., 2004).   
 
Wagner syndrome and erosive vitreoretinopathy  
Wagner syndrome was first described in 1938 as a non systemic ocular abnormality 
(Wagner, 1938).  The clinical appearance of patients with Wagner syndrome includes 
syneresis of the vitreous, cataract, high myopia, night blindness and retinal 
detachment and has been reviewed recently (Kloeckener-Gruissem et al., 2009).  
Linkage analyses revealed a region on chromosome 5 to which a candidate gene, 
VCAN (formerly CSPG2), encoding the extracellular matrix protein versican, localized 
(Brown et al., 1995; Perveen et al., 1999). It still took several years until the first 
causative mutation in VCAN was identified in a Japanese family with Wagner disease 
(Miyamoto et al., 2005), which was followed by the identification of further mutations 
in the original Wagner family (Kloeckener-Gruissem et al., 2006) as well as in 
additional families (Meredith et al., 2006; Mukhopadhyay et al., 2006; Ronan et al., 
2009).  All mutations localize to splice donor or acceptor sites that affect splicing of 
exon 8.  VCAN is expressed in the vitreous and in cartilage and exists in four splice 
variants that differ in the presence or absence of exon 7 and exon 8.  The levels of 
VCAN variant V2 (no exon 8) and V3 (no exon 7) transcripts from patients’ blood or 
lymphoblastoid cell lines are highly elevated (Mukhopadhyay et al., 2006), indicating 
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quantitative alterations of the naturally occurring splice variants as possible 
pathogenic mechanism.  
A family with ERVR was also found to segregate a splice site mutation in VCAN 
(Mukhopadhyay et al., 2006), suggesting that the two syndromes, Wagner and ERVR, 
are allelic, as it was previously anticipated based on mapping data (Black et al., 1999; 
Brown et al., 1994; Brown et al., 1995; Mukhopadhyay et al., 2006). Diagnostic 
mutation screening can benefit tremendously from these findings as sequencing of 
the rather large exon 7 (2.961 kb) and exon 8 (5.262 kb) can initially be avoided by 
focusing on intron-exon sequences of exon 7 and exon 8.   
 
2.4.2 Exudative vitreoretinopathies (EVRs)  
 
EVR is characterized by an incomplete blood vessel development in the retinal 
periphery, as well as by retinal folds and retinal detachment. The clinical diagnosis is 
usually made in the first years of life. There may be a decreased visual acuity due to 
macular folds or detachment. Upon fluorescein angiography, the retinal periphery 
appears avascular. A fibrovascular mass may develop that is associated with retinal 
exudates. This mass may extend to the ciliary body and peripheral lens capsule. The 
clinical manifestations are highly variable and some patients do not experience 
dramatic visual impairment. The inheritance patterns include autosomal dominant 
and recessive as well as X-linked transmission of the mutations. Currently three 
genes are known to carry mutations (Figure 5, Table 6) but there might be additional 
genetic defects in other genes. The first gene identified in this disease is the X-linked 
Norrie disease pseudoglioma gene (NDP) (Chen et al., 1993). Mutations in this gene 
lead usually to a severe disease, designated Norrie disease (ND) (Berger et al., 
1992a; Berger et al., 1992b; Berger, 1998; Chen et al., 1992; Meindl et al., 1992). 
This disease is characterized by congenital blindness and progressive hearing 
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impairment, starting in the first or second decade of life. In some cases, mental 
retardation or autistic features and behavioral manifestations are observed. Since 
mutations are X-linked recessive, only males are affected although exceptions exist, 
where female carriers also show symptoms (Sims et al., 1997; Yamada et al., 2001). 
There is a wide spectrum of mutations in this gene (please refer to the following 
website, where more than 100 mutations are summarized: 
http://www.medmolgen.uzh.ch). Remarkably, the same amino acid substitution can 
lead to either classic Norrie disease or EVR. For example the mutation p.R121W 
results in classic or mild ND, but was also found in EVR (Kellner et al., 1996; Meindl 
et al., 1995; Shastry et al., 1995; Shastry et al., 1997a; Wu et al., 2007). The same 
amino acid substitution was reported to be associated with retinopathy of prematurity 
(Shastry et al., 1997b), which is not a monogenetic trait but also might involve 
genetically predisposing factors.  
Similar observations were reported in the literature for other amino acid substitutions 
in the NDP gene, for example p.I18K, p.R38C, p.K54N, p.K58N, p.R74C, p.C96Y 
and p.R121Q, all of which are associated with Norrie disease or EVR (Berger et al., 
1992b; Boonstra et al., 2009; Fuchs et al., 1996; Fuentes et al., 1993; Kondo et al., 
2007; Meindl et al., 1992; Meindl et al., 1995; Riveiro-Alvarez et al., 2005; Royer et 
al., 2003; Shastry et al., 1999; Shima et al., 2009). Because of the frequent reports of 
a variable clinical expressivity or manifestations of different mutations, it is difficult to 
predict the clinical course of the disease for a specific mutation. 
In addition to NDP, three other genes were found to be mutated in EVR: Frizzled-4  
(FZD4) (Robitaille et al., 2002), the low density lipoprotein receptor-related protein 5 
gene (LRP5) (Jiao et al., 2004), and tetraspanin 12 (TSPAN12) (Nikopoulos et al., 
2010; Poulter et al., 2010). Similar to NDP mutations, pathogenic LRP5 sequence 
alterations also lead to extra ocular symptoms. The disease is designated 
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osteoporosis pseudoglioma syndrome (OPPG). FZD4 mutations are dominant while 
LRP5 mutations are recessive, although a bone phenotype can be present in LRP5 
mutation carriers. 
These four genes and their proteins are functionally linked. It was found that Norrin is 
a ligand of the receptor pair FZD4 and LRP5. Upon Norrin binding, the canonical Wnt 
signaling pathway is induced in the target cell (Xu et al., 2004). This was shown by 
using reporter gene assays in cell culture. The functional interaction of Norrin, FZD4, 
LRP5 and TSPAN12 during retinal angiogenesis is also supported by phenotypic 
similarities observed  in human patients but also in the respective mouse models 
(Berger et al., 1996; Hsieh et al., 2005; Junge et al., 2009; Luhmann et al., 2005b; 
Luhmann et al., 2005a; Luhmann et al., 2008; Schäfer et al., 2008; Wang et al., 2001; 
Ye et al., 2009). 
 
3. Syndromic retinal diseases 
 
3.1 Usher syndrome 
 
In Usher syndrome, not only the retina is affected by the disease but also the inner 
ear. The disease is a combination of retinitis pigmentosa (RP) and sensorineural 
deafness or hearing impairment. Clinically, Usher syndrome is classified in three 
subtypes, depending on the severity and age of onset of disease manifestations in 
retina and ear. The most severe form is Usher syndrome type 1. Patients with this 
subtype have profound and congenital deafness and vestibular dysfunction, leading 
to delayed motor development, and adolescent-onset RP. Usher type 2 is less 
severe with normal vestibular function, mild to severe sensorineural hearing loss, 
which is non-progressive in most cases, and a later onset of RP in adolescence or 
adulthood. Patients with Usher 3 also have a milder but progressive form of deafness 
and approximately 50% also manifest vestibular problems. The mode of inheritance 
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for all three types of Usher syndrome is autosomal recessive. It accounts for 
approximately half of the cases of deaf-blind patients (Vernon, 1969) and affects 
between 1:12000 or 1:30000 people in different populations. The general frequency 
of RP is about 1 in 3000 to 1 in 5000 individuals, the Usher cases may represent 
between 10-30% of all autosomal recessive RP cases (Hartong et al., 2006). So far, 
mutations in 10 different genes  (Figure 2, Table 8) have been associated with Usher 
syndrome (Bolz, 2009; Saihan et al., 2009; Williams, 2008). Two major loci for Usher 
type 1 and 2 are myosin 7A (MYO7A) and usherin (USH2A), respectively (Eudy et al., 
1998; Weil et al., 1995). MYO7A mutations account for 30-50% of Usher 1 cases. 
The gene product is an actin-based motor protein. In addition to its motor domain, 
this exceptionally large protein (5202 amino acid residues) also contains additional 
domains which are responsible for the interaction with other cellular proteins and may 
be responsible for the intracellular transport of proteins through the connecting cilium 
of photoreceptor cells. This is supported by the abnormal accumulation of opsin 
within the connecting cilium in Myo7a-deficient mice (Liu et al., 1999). Usherin 
(USH2A) is most likely a membrane anchored extracellular protein which is important 
for photoreceptor cell maintenance and proper development of sensory hair cells 
within the cochlea (Liu et al., 2007). The Usher-associated proteins form a complex 
network which is important for protein transport in photoreceptor and hair cells. Usher 
1D (cadherin 23) and 1F (protocadherin-15) are cell adhesion molecules and might 
be important for the structural integrity of the tissue. 
 
3.2 Bardet Biedl syndrome 
 
Bardet-Biedl syndrome (BBS) is caused by mutations in at least 13 genes (see 
Figure 2, Table 8) (Ansley et al., 2003; Badano et al., 2003a; Chiang et al., 2006; Fan 
et al., 2004; Katsanis et al., 2000; Li et al., 2004; Mykytyn et al., 2001; Mykytyn et al., 
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2002; Nishimura et al., 2001; Nishimura et al., 2005; Stoetzel et al., 2006; Stoetzel et 
al., 2007). The phenotypic variability among patients, even within one family, is 
significant. The primary features include retinal degeneration, obesity, polydactyly, 
renal and genital abnormalities, and learning disabilities. A number of secondary  
features, e.g. situs inversus, developmental delay, diabetes mellitus, and strabismus, 
have also been observed in BBS patients (compare www.geneclinics.org or 
(Katsanis et al., 2001b)). 
In a surprisingly short time period of around 8 years, 12 genes have been associated 
with BBS. This was even more surprising since the disease is rare and affects only 1 
individual in 120000 Caucasians. Isolated populations with an increase in 
consanguinity accelerated gene identification using linkage or homozygosity mapping. 
The first gene has been discovered in the year 2000 on the basis of linkage in 
Newfoundland families. Linkage intervals suggested overlapping mapping positions 
with the clinically similar McKusick-Kaufman syndrome gene MKKS. Co-segregation 
of mutations in BBS6 patients within the MKKS gene confirmed that the two 
syndromes are allelic (Katsanis et al., 2000), but genetic heterogeneity suggested the 
existence of additional BBS genes.  Combining classical genetic mapping 
technologies with an in silico-based method of comparing genomes of ciliated and 
non-ciliated species allowed the identification of BBS3, BBS5, and BBS9. 
Furthermore, BBS7 as well as the causative gene within the BBS1 locus were 
discovered on the basis of protein homology with BBS2. Protein comparisons also 
lead to the identification of BBS8, which shows sequence similarity to BBS4. 
Moreover, the predicted function of the gene product of BBS6/MKKS as a 
chaperonin-like molecule led to the identification of the most recently discovered 
BBS-associated gene BBS12; the sequence homology to chaperonins indicated a 
priority for a candidate within the linkage interval of consanguineous families 
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(Stoetzel et al., 2007). Moreover, BBS10 is also a possible chaperonin (Stoetzel et al., 
2006). Evolutionary conservation indicated that BBS 6, 10, and 12 are part of a 
separately evolved branch of the chaperonin gene family and thus might be involved 
in protein folding. Nevertheless, protein folding seems not to be the main function 
linking all BBS genes. A large body of work rather indicates that ciliary transport and 
basal body properties are disturbed in BBS patients. This observation is also 
supported by a number of clinical phenotypes, e.g. situs inversus (caused by 
disturbed ciliary function in the node of the developing embryo), as well as renal 
cysts (induced by dysfunction of cilia in the renal tubule or retinitis pigmentosa 
causes by inhibition of transport processes through the connecting cilium of the 
photoreceptor). Indeed, BBS1 is associated with vesicular transport processes of the 
cilium, indictated by the finding that BBS1 binds to Rabin-8 which in turn activates 
rab-8, a molecule that targets vesicles to cilia (Nachury et al., 2007). A similar 
process might also affect transport efficiencies across the photoreceptor connecting 
cilium and cause retinal degeneration. This hypothesis is supported by the finding 
that rhodopsin is less efficiently transported from the inner segment to the outer 
segment of rod photoreceptors in BBS2 knock out mice (Nishimura et al., 2004). 
Furthermore, complexes containing chaperones, rhodopsin, and other photoreceptor-
specific proteins have been associated to intraflagellar transport processes through 
the connecting cilium of rods (Bhowmick et al., 2009). 
Disturbed transport processes across cilia may even influence basic cellular signaling 
cascades, as exemplified by the finding that a BBS4 knock down resulted in reduced 
inhibition of the canonical Wnt signaling pathways after stimulation with the Wnt 
effector Wnt3a (Corbit et al., 2008; Gerdes et al., 2007). However, the exact 
mechanism underlying the connection between cilia and Wnt signaling is not 
completely understood (He, 2008). 
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Typically, BBS mutations are autosomal recessive. The most frequently mutated BBS 
gene is BBS1, which affects over 20% of the patients (Katsanis, 2004). Moreover, the 
hot spot mutation p.M390R is found in up to 80% of BBS1 patients (see 
www.geneclinics.org). The second most frequent hot spot mutation p.C91LfsX4 in 
BBS10, which affects around 50% of the BBS10 alleles. Thus, a significant portion of 
the cases can be identified by screening only 2 exons in two BBS genes. 
Nevertheless, 20-30% of the patients have no detectable mutations in the known 
genes (see www.geneclinics.org), which strongly indicates that further BBS genes 
await identification.  
In some pedigrees the disease does not follow the classical autosomal recessive 
pattern, but seems to be transmitted in a digenic or oligogenic way. Individuals have 
been documented who showed two mutations in a single BBS gene in addition to a 
sequence alteration in a different BBS gene (Beales et al., 2003). Further support for 
the digenic or oligogenic inheritance is provided from individuals who carry two 
known mutations in BBS1 (p.M390R) without expressing the phenotype. Significantly, 
a case has been identified where only three nonsense mutations in two different BBS 
genes cause disease manifestations while two nonsense mutations on both alleles of 
a single gene do not lead to symptoms (Katsanis et al., 2001a). Nevertheless, in 
cases with oligogenic inheritance, the third mutation is often a missense mutation 
with uncertain pathogenicity. This may also indicate that additional mutations act as 
modifiers influencing the degree of phenotypic expression in patients (Badano et al., 
2003b). Consequently, different disease severities might be explained depending on 
the particular ‘BBS environment’ of the individual patient. The molecular basis for 
such ‘BBS environments’ has been reported (Nachury et al., 2007). Nachury et al. 
showed that seven BBS proteins build an interaction complex, called the BBSome. 
Using BBS4 as bait, stoichiometric amounts of BBS1, BBS2, BBS5, BBS7, BBS8, 
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and BBS9 have been isolated within a cilia-associated complex. Inhibition of 
members of the BBSome leads to disturbed ciliary properties. Thus, it may well be 
that additional mutations within the BBSome affect the phenotypic presentation of the 
respective patient. It will be interesting to further analyze these complex correlations, 
e.g. by crossing the homozygous BBS1 p.M390R knockin mouse model (Davis et al., 
2007) into different genetic backgrounds to determine the influence of modifiers for 
the disease expression. Alternatively, generating double or tripple knockout BBS 
mice might provide further clues to the genetic interaction between BBS genes and 
their consequences for the phenotype. In the light of modifier action or oligogenetic 
inheritance, it is interesting that while most BBS patients show severe retinal 
degeneration, mild forms have also been reported (Azari et al., 2006; Gerth et al., 
2008; Heon et al., 2005). In addition, different phenotypic expressions like retinitis 
pigmentosa and macular degeneration were reported in patients with a homozygous 
BBS1 mutation p.M390R (Azari et al., 2006). This heterogeneity of the phenotype 
may be best understood through the action of genetic modifiers.   
Analogous to the oligogenic influence on the BBS phenotype, other cases of RP or 
retinal degeneration are likely to be influenced by modifiers. As an example, 
mutations in the RPGR gene may cause X-linked recessive RP, but occasionally is 
associated with additional phenotypes like hearing defects, primary ciliary dyskinesia, 
or sinorespiratory infections (Iannaccone et al., 2003; Moore et al., 2006; Zito et al., 
2003). Furthermore, the disease expression largely varies even within one family. 
Since RPGR binds a number of retinal degeneration-associated interaction partners 
at the molecular level (e.g. RPGRIP1, SMC1 and 3, CEP290 or Nephrocystin 5), it 
seems plausible that modifying sequence alterations affecting the ‘RPGR 
interactome’ would give rise to altered phenotypic severity or additional clinical 
manifestations. 
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3.3 Senior Loken Syndrome / Nephronophthisis (SLSN) 
 
Patients with SLSN manifest kidney and eye diseases. The kidney phenotype is 
designated nephronophthisis (NPHP) and the retinal degeneration can be RP of 
varying degrees or LCA, as in the case of NPHP6/SLSN6. So far, six genes were 
shown to carry mutations in affected individuals (Figure 2, Table 8). Recent studies 
have shown that the respective gene products are involved in the structure or 
function of motile and primary cilia. Therefore the term ´ciliopathies´ is also used for 
this group of diseases, as it is for primary ciliary dyskinesias. Most prevalent are 
mutations in the NPHP1/SLSN1 gene, which were found in approximately 20% of the 
families. All other genes are affected significantly less frequent (0.1-3%) (Hildebrandt 
et al., 2009). NPHP1/SLSN1 localized to the transition zone of the cilium and were 
found to interact with other proteins which can carry mutations in patients with Senior 
Loken syndrome, including inversin, nephrocystin-3 and nephrocystin-4 (Fliegauf et 
al., 2006; Mollet et al., 2002; Olbrich et al., 2003; Otto et al., 2003). Although 
molecular diagnosis is possible in some families, the majority of cases 
(approximately 70%) can not be explained by mutations in the genes known so far. 
 
3.4 Refsum disease 
 
Refsum disease belongs to the peroxisome biogenesis disorders (PBD), which also 
include Zellweger syndrome, neonatal adrenoleukodystrophy, and rhizomelic 
chondrodysplasia punctata. The first symptoms may arise during late childhood and 
include defective night vision, progressive RP, mental retardation, and anosmia. 
During disease progression additional features like polyneuropathy, deafness, ataxia, 
cardiac arrhythmias as well as skin abnormalities (ichthyosis) may establish. In 
addition, about one third of patients have bone manifestations in hand and feet 
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(Jansen et al., 2004). Mutations in five genes were detected in affected individuals 
(Figure 2, Table 8) (Furuki et al., 2006; Geisbrecht et al., 1998; Jansen et al., 2004; 
Matsumoto et al., 2003; Shimozawa et al., 1999). The functional spectrum of these 
genes comprises fatty acid oxidation, peroxisomal protein import as well as 
peroxisome biogenesis. 
 
3.5 Joubert syndrome 
 
Joubert syndrome is a rare (1/100000) clinically and genetically heterogeneous group 
of developmental disorders, which is inherited in an autosomal recessive pattern. 
One exception has recently been described with an X-linked recessive mode of 
inheritance (Coene et al., 2009). Characteristic features are hypoplasia of the 
cerebellar vermis with the neuroradiologic “molar tooth sign” and other neurologic 
symptoms including dysregulation of breathing pattern and a general developmental 
delay.  Additional variable features which include polydactyly, hepatic fibrosis, renal 
disease and retinal dystrophy are often collectively referred to as cerebello-oculo-
renal syndrome (CORS), which is also associated with primary ciliary dysfunction.  
The clinical heterogeneity is reflected by genetic heterogeneity as eight genes have 
been described to be involved in Joubert syndrome (Figure 2, Table 8). Generally, 
mutations in one of the eight genes do not necessarily lead to all possible 
phenotypes. Mutations in the Abelson’s helper integration 1 gene (AHI1) also known 
as JBTS3 (Dixon-Salazar et al., 2004; Ferland et al., 2004) are associated mainly 
with symptoms restricted to the central nervous system.  Several exceptions were 
reported where patients who carried mutations in AHI1 showed in addition a retinal 
phenotype that could range from RP to LCA (Valente et al., 2006). Although the 
function of the AHI1 protein is not known, the presence of a putative Src homology 3 
(SH3) domain and six WD40 repeats suggests that AHI1 mediates the formation of 
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large multi-protein complexes. Furthermore, the AHI1 protein may play also a role in 
common disorders that affect cognition and behavior since sequence variants of 
AHI1 were found to associate with autism (Alvarez Retuerto et al., 2008).  Deletion 
mutations in another gene, NPHP1, also known as JBTS4, have been found in few 
patients with Joubert syndrome (Valente et al., 2006) and Senior-Loken syndrome 
(SLSN), a recessive form of RP (Caridi et al., 1998), although most mutations are 
responsible for isolated juvenile nephronophthisis. SLSN will be described elsewhere 
in this review.  The gene product of NPHP1 is nephrocystin-1 and with the help of 
mouse models its role in intraflagellar transport could be demonstrated (Jiang et al., 
2009).  Another component of the ciliary complex is a putative 2480-residue 
centrosomal protein encoded by CEP290. Mutations in this gene were associated 
with several aspects of Joubert syndrome, including those of retina and kidney 
(Brancati et al., 2007; Valente et al., 2006). The severity of the ocular phenotype in 
these patients is similar to that characteristic of the Senior-Loken syndrome. It is 
noteworthy that mutations in CEP290 have been shown to be the most frequent 
cause of isolated LCA, in the absence of any renal or neurological involvement (den 
Hollander et al., 2006; Perrault et al., 2007). Interestingly, one Joubert patient with a 
homozygous deletion affecting exon 36 of CEP290 showed the LCA ocular 
phenotype and complete situs inversus, suggesting a strong overlap between 
Joubert syndrome and other ciliopathies (Brancati et al., 2007).  This overlap is 
further supported by association of mutations in the gene CC2D2A with Joubert 
syndrome, including retinal defects.  The CC2D2A product interacts in vitro with the 
CEP290 protein (Gorden et al., 2008) and both proteins localize to the basal body.  
Mutations in the gene ARL13B, encoding a further ciliary protein, ADP-ribosylation 
factor-like protein13B, can also lead to Joubert syndrome (Cantagrel et al., 2008).  
ARL13B’s involvement in the retinal defect in Joubert syndrome has not been 
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completely understood since only one Joubert syndrome patient displayed evidence 
of mild pigmentary retinopathy but normal ERG. Finally, the gene RPGR-interacting 
protein 1-like (RPGRIP1L), encoding a ciliary protein with specificity for the cilium of 
photoreceptors, is mutated in patients with CORS; among them also one patient with 
retinitis pigmentosa (Delous et al., 2007). Further screening did not yield additional 
individuals with retinitis pigmentosa, making it likely that mutations in this gene are 
largely confined to the cerebro-renal subgroup of Joubert syndrome (Brancati et al., 
2008).  Frameshift mutations in the gene OFD1, which is known for its association 
with oral-facial-digital syndrome type 1, were recently found in a family segregating 
X-linked Joubert syndrome with RP (Coene et al., 2009). As the previous examples 
showed, OFD1 also interacts with a component of the ciliary protein complex. 
Depending on the dominant or recessive phenotype, interaction with LCA5 encoded 
ciliary protein lebercillin either abolishes or reduces binding (Coene et al., 2009). 
These examples demonstrate the necessity of a functional ciliary complex and 
intraflagellar transport for normal retinal function. The findings also emphasize the 
genotypic-phenotypic complexity of the syndromic diseases with retinal involvement 
as stated elsewhere through out this review. Most recently, mutations in the gene 
TMEM216, coding for a short protein of 87 amino acids predicted to form two 
transmembrane domains, were associated with Joubert syndrome type 2 (Edvardson 
et al., 2010). It is speculated, that it is part of the primary cilium, similar to TMEM67, 
which is also involved in Joubert syndrome (Baala et al., 2007; Dawe et al., 2007). 
 
 
3.6 Alagille syndrome (ALGS) 
 
Mutations in jagged 1 (JAG1) and the notch 2 receptor cause Alagille syndrome 
(ALGS1 and ALGS2, Figure 4, Table 5)(McDaniell et al., 2006; Oda et al., 1997). The 
majority of cases can be explained by sequence alterations in JAG1. JAG1 is a 
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transmembrane protein that constitutes a ligand in the notch pathway. Since the 
notch signalling is an important developmental pathway, relevant for several tissues 
(reviewed by (Kopan et al., 2009), it is not surprising that ALGS1 includes a wide 
range of clinical manifestations (hepatic, cardiac, vascular, skeletal, ocular, facial, 
renal, pancreatic, and neuronal) (Piccoli et al., 2001). Clear genotype-phenotype 
correlations have not been observed in ALGS. Moreover, the phenotypes are highly 
variable among patients with JAG1 mutations (Colliton et al., 2001). Ocular features 
of ALGS may include optic disc drusen, angulated retinal vessels, a pigmentary 
retinopathy, and posterior embryotoxon (Kim et al., 2007). The disease is rare and 
affects approximately 1 in 100000 individuals. The mutations are inherited in an 
autosomal dominant pattern with reduced penetrance. Interestingly, the majority of 
the JAG1 mutations are nonsense mutations or small deletions leading to premature 
termination codons. Furthermore, some deletions affect the entire coding region of 
JAG1. This supports the hypothesis that a reduced gene dosage (haploinsufficiency) 
may be the basis of the disease (Spinner et al., 2001). 
 
 
3.7 Alstrom syndrome (ALMS) 
 
Alstrom syndrome is a rare (less than 200000 affected individuals in US population) 
autosomal recessive disorder characterized by a progressive cone-rod photoreceptor 
dystrophy, sensorineural hearing loss, obesity and type II diabetis.  In many patients 
cardiomyopathy, urological dysfunction and pulmonary, hepatic and renal failure 
develop as well.  Despite its similarities to Bardet-Biedl syndrome, mental retardation, 
polydactyly and hypergonadism do not belong to the repertoire of features in Alstrom 
syndrome.  Disruption of the gene ALMS1 (Figure 3, Table 3), located on 
chromosome 2, was found to associate with the syndrome (Collin et al., 2002; Hearn 
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et al., 2002).  The gene does not share identifiable homologies to other known genes 
or proteins and the proteins´ function is unknown (Marshall et al., 2007).  ALMS1 is 
widely expressed and the protein subcellularly localizes to centrosomes and basal 
bodies of ciliated cells (Collin et al., 2002; Hearn et al., 2002). Among the identified 
mutations are nonsense and frame shift variations that are predicted to result in 
prematurely terminated proteins (Marshall et al., 2007).  Exon 16 appears to contain 
a mutation hotspot as evidenced by the fact that 12% of all mutant alleles carry the 
deletion c.10775delC (Marshall et al., 2007). Patients with mutations in exon 16 also 
seem to express a more severe phenotype (Marshall et al., 2007).  Phenotype-
genotype correlations were suggestive between alterations in exon 16 and the retinal 
degeneration feature, if it manifested before the age of one year (Marshall et al., 
2007).  Alm1 knockout mice aided in an attempt to understand the function of ALMS1.  
With respect to the retinal phenotype, reduced b-wave responses in the ERG were 
observed that were followed by photoreceptor degeneration.  Accumulation of 
intracellular vesicles in the inner segments and mislocalization of rhodopsin to the 
outer nuclear layer indicate that ALMS1 may play a role in intracellular trafficking 
(Collin et al., 2005). As the morphological appearance of the cilia was not altered (Li 
et al., 2007) it seems likely that a functional rather than structural effect may be 
responsible for the phenotype. 
 
3.8 Neuronal ceroid lipofuscinosis (NCLs or CLNs) 
 
Neuronal ceroid lipofuscinosis are neurodegenerative lysosomal storage diseases. 
They are characterized by the accumulation of autofluorescent material in different 
cell types including neurons. Clinical manifestations comprise epileptic seizures, 
progressive psychomotor retardation, visual loss, and premature death. Mutations 
occur in at least eight different genes (Figure 4, Table 5). The mode of inheritance is 
47 
Berger et al., Manuscript for Progress in Retinal and Eye Research, (amended March 12 2010)
The molecular basis of human retinal and vitreoretinal diseases 
 
autosomal recessive. The age of onset is variable and defines, together with clinical 
manifestations, five different forms of NCLs (Kousi et al., 2009): 1. congenital form 
(CLN10), 2. infantile form (INCL, CLN1), 3. late infantile form (LINCL, CLN2), 4. 
juvenile form (JNCL, CLN3), and 5. the adult form (ANCL, CLN4). Some of these 
forms are genetically heterogeneous in terms of genes where mutations have been 
described which lead to the clinical symptoms. 
The infantile and late infantile forms are caused by mutations in the genes encoding 
the lysosomal enzymes palmitoyl-protein thioesterase 1 (PPT1) and tripeptidyl 
peptidase (TPP1), respectively (Sleat et al., 1997; Vesa et al., 1995). Mutations in the 
gene coding for cathepsin D, a lysosomal proteinase, were found in patients with 
congenital as well as later-onset NCLs (Fritchie et al., 2009; Siintola et al., 2006; 
Steinfeld et al., 2006). Other NCL-associated genes encode lysosomal or 
endoplasmic reticulum proteins. CLN3 seems to be a lysosomal membrane protein 
(International Batten Disease Consortium, 1995; Jarvela et al., 1998). CLN5 is 
expressed in cerebellar Purkinje cells, cerebral neurons, hippocampal pyramidal cells, 
and hippocampal interneurons. Thus, the expression pattern correlates with 
degenerated brain regions in CLN5 patients. Cell culture experiments revealed that 
CLN5 is a soluble lysosomal glycoprotein (Holmberg et al., 2004; Isosomppi et al., 
2002). The CLN6 protein localized to the membranes of the endoplasmic reticulum 
(Gao et al., 2002; Heine et al., 2004; Mole et al., 2004). The CLN7 gene codes for 
the lysosomal transporter MFSD8 (Siintola et al., 2007) and CLN8 for a membrane 
protein that localizes to the ER and ER-Golgi intermediate structure (Lonka et al., 
2000; Ranta et al., 1999).  
 
3.9 Primary ciliary dyskinesia (PCD) 
 
48 
Berger et al., Manuscript for Progress in Retinal and Eye Research, (amended March 12 2010)
The molecular basis of human retinal and vitreoretinal diseases 
 
PCD is a rare, autosomal recessive disease with a defect in ciliary function. 
Progressive sinopulmonary disease is one of the cardinal features and approximately 
half of the patients have situs inversus (mirror orientation of thoraco-abdominal 
organs). Also male infertility is common and complex congenital heart disease can 
occur (Leigh et al., 2009a; Leigh et al., 2009b). The combination of situs inversus 
totalis, chronic sinusitis and bronchiectasis is also known as the Kartagener triad. 
Almost all men with PCD are infertile from sperm immotility. Additional symptoms or 
clinical manifestations may include hydrocephalus, retinitis pigmentosa, polycystic 
kidney disease, liver cysts, biliary artresia. All those features are rare in PCD. Six 
genes are known to be mutated in PCD disease (Figure 2, Table 8) (Bartoloni et al., 
2002; Failly et al., 2008; Guichard et al., 2001; Ibanez-Tallon et al., 2002; Loges et al., 
2008; Omran et al., 2008; Pennarun et al., 1999; Schwabe et al., 2008). In addition to 
these genes an RPGR mutation was reported that leads to a combination of RP and 
PCD (Moore et al., 2006). Mutations in DNAI1 and DNAH5 are responsible for about 
half of the cases, while mutations in the other genes are rare (Escudier et al., 2009). 
 
3.10 Stickler syndrome 
Among the vitreoretinopathies Stickler syndrome may be the most frequent one and 
unlike the others, it shows syndromic characteristics.  The pattern of inheritance is 
autosomal dominant, with one published exception (Van Camp et al., 2006).  The 
syndrome is a connective tissue disorder that can include eye, ear, joints and facial 
features (www.genereviews.org).  Hearing problems can be conductive and 
sensorineural.  Craniofacial features may include midface hypoplasia, depressed 
nasal bridge, anteverted nares, micrognathia, cleft palate and glossoptosis.  The joint 
problems display hypermobility, mild spondyloepiphyseal dysplasia and also 
precautious osteoarthritis.  Here we will focus on the ocular features which include 
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myopia, cataract, vitreous anomalies and retinal detachment (also known as 
rhegmatogenous retinal detachment or RRD). The symptoms vary widely within and 
among Stickler families and individuals (Donoso et al., 2003) and some overlapping 
features with respect to the vitreous and retinal detachment have been observed with 
Marshall syndrome (OMIM 154780).  Based on the genetic cause and the pattern of 
inheritance different types of Stickler syndrome can be distinguished (Figure 5, Table 
6). Collagen plays an important role in the disease pathology of all types as has 
become clear from mutation analyses. The autosomal recessive form involves the 
COL9A1 gene (Van Camp et al., 2006) while the autosomal dominant form is caused 
by mutations in COL2A1, COL11A1 and COL11A2, all encoding different types of 
collagen (type II and type XI) constituting major components of the structural entities 
of cartilage and the vitreous.  Mutations in the latter gene do not seem to affect the 
vitreous (Sirko-Osadsa et al., 1998).  Additional Stickler loci are expected as not all 
families could be identified with mutations (Richards et al., 2002).  A potential 
candidate is the gene encoding the nuclear protein TIA-1, which regulates alternative 
splicing of COL2A1 (McAlinden et al., 2007).   
Mutations in COL2A1 comprise the majority of the genetic causes of Stickler 
syndrome.  In a tissue-specific event, COL2A1 transcripts undergo alternative 
splicing such that exon 2 containing transcripts are found in the vitreous and those 
lacking exon 2 in cartilage.  While mutations anywhere in the gene might give rise to 
both, systemic and ocular manifestation, one might expect that mutations in or near 
exon 2 would cause only ocular features.  Clinical heterogeneity can only to some 
extent be correlated with mutations in exon 2 (Donoso et al., 2003; McAlinden et al., 
2008), which is supported by the finding that the ocular phenotype is predominantly 
caused by premature termination codon (PTC) mutations in exon 2.  The same effect 
on splicing but via a different mechanism causes the c.170G<A (p.Cys57Tyr) 
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substitution, which lies within a cis regulatory region involved in splicing of the mature 
transcript (McAlinden et al., 2008). Interestingly, a change of the same amino acid to 
a stop codon (p.Cys57Stop) was associated with Wagner syndrome (Gupta et al., 
2002).  Since the two diseases share many similarities, the diagnosis may have been 
ambiguous (Richards et al., 2005). Taken together, differential splicing seems to be 
an important molecular mechanism for tissue-specific diseases, as has been 
observed for other syndromic diseases with ocular involvement and were discussed 
under RP.  Although haploinsufficiency is the proposed disease mechanism for 
Stickler syndrome, missplicing leads frequently to a dominant-negative effect with a 
more severe phenotype (Richards et al., 2005).   
Mutations in COL11A1 are predicted to disrupt or alter collagen type XI. Among them 
are few deletion and insertion mutations but the majority of mutations affect splice 
sites at different intron-exon boundaries (Majava et al., 2007).  We interpret that the 
effect of these mutations is comparable to those described above for COL2A1.   
The question whether different, yet often overlapping features of disease conditions, 
are due to allelic states of a given gene can be answered by mutation analysis.  
Using this approach, Marshall syndrome, which includes vitreous and retinal 
abnormalities, can be considered allelic to Stickler syndrome since mutations in 
COL11A1 cause both (Majava et al., 2007). 
 
4. Genetic testing and counselling 
In order to diagnose and counsel patients and their families, knowledge about their 
disease-causing mutation is essential. Especially for genetic counseling, targeted 
clinical characterization and gene therapeutic interventions, the precise molecular 
diagnosis is very important. Unfortunately, the disease-causing mutation is often 
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difficult to identify due to the genetic heterogeneity and clinical variability of retinal 
diseases. 
Several strategies do exist and novel technologies are emerging that increase the 
chance to identify the causative mutation in patients. For this purpose, knowledge of 
the pedigree is of utmost importance. It often provides significant clues to the 
selection of genes implicated for molecular genetic testing. In cases of autosomal 
dominant RP, the likelihood to identify the causative mutation among the five most 
frequently affected genes is approximately 50%. These five genes are rhodopsin 
(RHO), peripherin 2 (PRPH2), retinitis pigmentosa 1 (RP1), pre-mRNA processing 
factor 31 (PRPF31), and inosine monophosphate dehydrogenase 1 (IMPDH1). The 
best candidate for adRP is rhodopsin, which accounts for up to 30% of the cases 
(Kennan et al., 2005), whereas the other candidates have frequencies between 5 and 
20%. Moreover, these five adRP genes comprise a total of only 40 coding exons, a 
number that seems manageable to be analyzed by conventional sequencing or other 
appropriate methods. Nevertheless, in cases of incomplete penetrance (carriers of 
the mutation are occasionally not affected), the collection of candidate genes is much 
smaller. Only three of the 19 adRP genes have been associated with incomplete 
penetrance (PRPF31, PAP1, and RP1). To optimize mutational screening 
procedures for such cases, a detailed case history including a family pedigree over 
several generations is needed to recognize incomplete penetrance of the phenotype. 
In cases where the pedigree suggests X-linked inheritance within the family, RPGR 
and RP2 are the only candidates associated with RP so far. In addition, almost all 
cases can be explained by mutations in either RPGR (up to 80% of the cases) or 
RP2 (up to 20% of the cases) (Neidhardt et al., 2008; Roepman et al., 1996b; 
Schwahn et al., 1998). A screening strategy starting with a mutation hot spot in 
RPGR followed by sequencing of other exons has been shown to be successful in 
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most cases and to reduce costs and efforts (Neidhardt et al., 2008). Additional loci on 
the X-chromosome have been mapped, but the corresponding genes have not yet 
been identified. Interestingly, RPGR mutations may also affect female carriers and 
thus should not be associated with classical X-linked recessive inheritance. The 
genetic basis for this observation is still unclear. Since skewed X-inactivation has not 
been identified in affected female carriers so far, genetic or environmental modifiers 
may be relevant too. In contrast to X-linked RP, the candidate selection is more 
difficult in cases with autosomal recessive inheritance. Promising candidate genes for 
arRP are PDE6alpha and PDE6beta that together explain about 5-10% of the cases 
(Daiger et al., 2007). USH2A is a gene frequently found to be mutated in arRP (up to 
20% of the cases), but is also associated with Usher Syndrome ((Hartong et al., 2006) 
and references therein). Furthermore, ABCA4 and RPE65 often show RP-associated 
mutations, but classically cause Stargardts disease or LCA (Figures 2, 3, 4 and 6, 
Tables 2, 3 and 5). Thus, a thorough clinical characterization of the phenotype 
including syndromic features will further facilitate the selection of candidate genes for 
molecular genetic testing in a patient with arRP. 
Following these screening strategies, the samples without identified mutations may 
be included in research programs to identify novel loci and disease-associated genes. 
Methods that are used to further characterize such samples often include array 
technologies (SNP arrays) with the aim to identify linkage intervals in families with 
multiple affected members or homozygous regions in the genome of consanguineous 
families. Furthermore, array technologies may be used to directly screen for 
mutations (Koenekoop et al., 2007).  
In particular, genetic testing for the large gene ABCA4 and for all recessive or 
dominant RP genes requires efficient diagnostic tests in order to examine the DNA 
sample of a patient in an affordable amount of time. One such tool for mutation 
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detection represent microarrays. This technique has been established for several 
retinal diseases (Cremers et al., 2007; Jaakson et al., 2003; Zernant et al., 2005). 
Also for CSNB, the large number of genes and mutations associated with this 
disease are challenging for confirmation of the clinical diagnosis. Recently, a 
microarray has been developed which provides a fast and rather inexpensive tool to 
screen DNA samples from patients for known mutations in one of the above 
mentioned genes (Zeitz et al., 2009). However, with this diagnostic test only known 
sequence alterations can be detected as in the case of ABCA4 (Klevering et al., 
2004b). The most sensitive technology currently available for routine diagnostics is 
direct DNA sequencing in combination with multiple ligation-dependent probe 
amplification (MLPA), the latter of which can be used to reveal copy number 
variations, such as deletions or duplications.  
Another challenge for genetic testing is the interpretation of the results of these tests. 
Many of the DNA sequence variations lead to amino acid substitutions and it is 
difficult to predict the pathogenic effect for many of them. Therefore, functional 
assays are needed to characterize these sequence alterations. For example, ABCA4 
possesses an ATPase activity and it is possible to analyze specific missense 
mutations in cell culture assays and answer the question of a potential pathogenic 
effect (Sun et al., 2000). Due to the extensive individuality of pathogenic and non-
pathogenic sequence alterations, this approach is difficult to realize in a routine 
diagnostic setting. In addition, deep intronic mutations may be responsible for a 
significant number of cases and these are extremely difficult to be analyzed in 
functional assays.  
Today, the new (next generation) sequencing technologies enable us to collect up to 
500 million base pairs per single sequencing run at comparably low costs 
(Voelkerding et al., 2009). This will complement or even replace other methods to 
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identify mutations in genetically heterogeneous diseases, such as retinal 
degenerations and dysfunctions. 
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5. Therapeutic approaches to retinal degenerations 
 
The eye is ideally suited as a target organ for several different therapeutic 
approaches as it is easy to access and enables to monitor the application of 
therapeutics. It further allows a non-invasive follow up of therapeutic effects in vivo. 
Its interconnected system of spatially well organized cell types facilitates the 
application of therapeutics to the target cells. Moreover, the eye shows an efficient 
blood-retinal barrier that greatly reduces or even prevents exchange of therapeutics 
with other organs and thus may limit side effects and further therapy-provoked 
immune responses like inflammation. In contrast to non-syndromic retinal diseases, it 
will be difficult to treat extraocular symptoms in patients with a syndromic form of 
retinal degeneration, e.g. Refsum disease, Joubert syndrome, Bardet Biedl syndrome, 
or others.  
Different avenues are currently followed in order to treat patients with retinal diseases. 
These include the application of nutrition supplements or drugs, gene replacement 
strategies, transplantation and stem cell technologies, as well as the implantation of 
electric devices, known as retinal prosthesis. 
We will discuss two therapeutic approaches that have advanced from successful 
application in animal models to phase 1 and/or 2 clinical trials: One strategy involves 
neurotrophic and survival factors that have been shown, for example in animal 
models, to prolong the lifespan of affected retinal cells. The other one uses gene 
replacement. Both showed a significant success rate for several inherited retinal 
diseases. 
The ciliary neurotrophic factor (CNTF) yielded promising results in two phase 2 
studies. The therapeutic intervention, designated ´Encapsulated Cell Technology 
(ECT, (Lanza et al., 1996))´, involves intraocular implants containing human cells, 
which secrete CNTF (Emerich et al., 2008; Thanos et al., 2004). A therapeutic device, 
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designated NT-501, was developed recently. Treatment of more than 120 patients 
with RP revealed a positive biological effect in the retina and photoreceptors, as 
measured by optical coherence tomography (OCT). However, the patients have been 
monitored only for a relatively short period of time (12 months). Preliminary results of 
these trials are encouraging but a long term follow-up is needed to evaluate the 
success of treatment and possible adverse effects. A positive effect measured by 
OCT has also been observed in patients with the dry form of AMD and geographic 
atrophy who were treated with NT-501 implants. The wet form of AMD may also be 
treated by delivering a structural antagonist of VEGF to the affected eye. Possible 
application of encapsulated cell technology (ECT) in AMD treatment was recently 
initiated (NT-503). 
In therapeutic approaches that apply gene replacement technologies, viral vectors 
have frequently been used to transduce retinal cells with intact copies of the mutated 
gene. In most cases, either the recombinant adeno-associated virus (rAAV) or the 
lentivirus provided the basis for the viral shuttle. Since cell specificity, expression 
kinetics and packaging size differ significantly between these viruses, the selection of 
the optimal virus type is essential for the therapeutic outcome. Furthermore, 
combinations of different rAAV serotypes enable an even more controlled use of cell 
specificity and expression kinetics (Auricchio et al., 2005; Neidhardt et al., 2005). For 
example, the serotype rAAV2/4 is more specific to RPE than rAAV2/5, which 
additionally transduces photoreceptors (Acland et al., 2005; Weber et al., 2003). 
Their expression kinetics are similarly fast, while rAAV2/2-mediated expression is 
significantly slower. An advantage of the lentivirus is to host larger genes of interest 
than rAAV. It is specific to RPE cells after subretinal delivery (Tschernutter et al., 
2005). 
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LCA patients with RPE65 mutations were the first to be treated successfully by gene 
replacement therapies in three independent phase 1 clinical trials (Bainbridge et al., 
2008; Hauswirth et al., 2008; Maguire et al., 2008). These clinical trials have been 
stimulated by encouraging results in a naturally occurring dog model of RPE65 
mutations (Acland et al., 2001). It further seemed a promising target gene for 
replacement therapy since the RPE65 deficiency results in visual impairment due to 
depletion of visual pigment from the phototransduction cascade, but shows a high 
degree of preservation of anatomical features within the retina. Furthermore, RPE65 
is RPE specific and subretinal injection of viral shuttles can more efficiently transduce 
RPE than photoreceptor cells, possibly because of anatomical barriers. Together with 
the appropriate choice of rAAV serotypes for the transduction of RPE cells, the gene 
therapy of RPE65 mutations resulted in increased retinal sensitivity in young adult 
patients (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008). Some 
patients had improved visual abilities in dim light conditions although the effect was 
not detectable by ERG measurements. Importantly, significant side effects of the viral 
treatment have not been detected so far. Future evaluations of long-term effects will 
be needed to judge safety aspects and therapeutic potential of this first gene 
replacement therapy in the eye.  
In general, gene replacement is more feasible in patients with loss of function 
mutations, represented by either recessive or dominant haploinsufficient alleles. In 
contrast, dominant negative mutations require two steps of therapeutic intervention: (i) 
inactivation or depletion of the dominant negative gene variant or gene product and 
(ii) introduction and expression of the healthy gene copy. This two-step approach is 
more challenging but several strategies to accomplish this are available (Millington-
Ward et al., 1997). In addition, the discovery of RNA interference mechanism may 
provide a suitable tool for the specific removal of transcripts encoding dominant 
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negative protein species of a given gene. The development of current gene 
replacement therapies focusses on genes that are frequently affected by recessive 
mutations, including PDE, ABCA4, CNGB3, GNAT2, and AIPL1. 
Future candidate genes for clinical trials will be selected on the basis of successful 
treatment of an appropriate animal model, the frequency of the mutations found 
within the respective gene, and the significance of the benefit expected for the patient. 
Furthermore, it is well possible that existing therapies will be improved by gene 
therapy approaches. The treatment of AMD often requires repeated injection of 
rather expensive medications over years. Gene therapy could lead to a permanent 
presence of AMD therapeutic agents in the eye, thus substituting repeated injections. 
Moreover, one might speculate that drug-inducible expression systems will be 
applied to control expression of the therapeutic protein in the eye. Such systems 
would also be beneficiary to enable the adjustment of therapeutic concentrations 
towards inter-individual phenotype differences.  
In summary, gene therapy and the application of substances that prolong the lifespan 
of affected retinal cells offer a multitude of possibilities that will contribute to the 
treatment of retinal diseases and will help to slow down or even stop the progression 
of several blinding eye diseases in the near future. For some of them, knowledge of 
the disease causing mutation will be essential prior to a specific application. But for 
others, a more general therapeutic approach, like treatment with neurotrophic or 
antiapoptotic factors, will be possible without knowing the pathogenic gene variant. 
However, we do not yet know or understand how a specific genotype contributes to 
the therapeutic outcome. Therefore, genotyping of patients and a detailed 
comparison of the genotype with the course of the therapeutic intervention will 
provide important informations with regard to a combinatorial effect of DNA variants, 
environmental factors, and the procedure of treatment. 
59 
Berger et al., Manuscript for Progress in Retinal and Eye Research, (amended March 12 2010)
The molecular basis of human retinal and vitreoretinal diseases 
 
6. Conclusions and outlook 
 
The future in the field of retinal diseases will focus on the identification of additional 
genes, the development of efficient and reliable diagnostic tests, and most 
importantly on the development of treatment regimens.  
Disease gene identification has become much more efficient with the availability of 
the human genome sequence. What it needs today are comprehensive databases 
integrating genetic but also clinical data in order to perform a detailed genotype-
phenotype comparison. This can reveal important information not only to diagnose a 
disease in a patient or family for genetic counselling, but it may also have a predictive 
value with respect to the likelihood of disease development and choices of therapy. 
The recent progress in sequencing technology, including next and third generation 
sequencing, will provide sequence information of entire introns in addition to exons. It 
will further be feasible to sequence a complete set of genes with important functions 
in retina, RPE, vitreous, but also other ocular structures. This will lead to the 
identification of numerous DNA variations. The challenge is to discriminate between 
the causative mutations, modifying alleles or other sequence variants, which confer a 
risk or protection for the development of an ocular disease. To evaluate all these 
variants, bioinformatic tools as well as sequence variation databases and clinical 
data from patients are extremely important for the interpretation of the sequencing 
results. 
Current development of treatments is very encouraging and will improve the quality 
of life of a patient.  Nevertheless, years if not decades of work is ahead of us, which 
will deliver important and exciting results in basic research and therapy. 
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Figure Legends: 
Figure 1 
Classification of monogenic familial retinal and vitreoretinal diseases. The disorders 
are categorized according to the photoreceptor cell type or ocular structure which are 
affected by the disease. Rod as well as cone dominated diseases are subdivided in 
stationary (yellow) and progressive (red) forms. Generalized photoreceptor diseases 
and vitreoretinal diseases are predominantly progressive. The progressive forms are 
non-syndromic or part of a multiorgan disease (syndromic). The + signs indicate that 
detailed informations and further subclassifications are available in Figures 2 to 5. 
 
Figure 2 
Rod over cone photoreceptor diseases. The diseases are either stationary or 
progressive. Disease-causing mutations in different genes are dominant, recessive, 
or X-linked. In syndromic forms, RP occurs together with disease symptoms in non-
ocular tissues or organs. The respective genes are indicated by gene symbols. 
 
Figure 3 
Cone over rod photoreceptor diseases. The stationary forms affect color vision. The 
progressive cone diseases can be subdivided in cone and cone rod dystrophies as 
well as macular degenerations. Both occur syndromic or non-syndromic. The 
different genes involved in these diseases are indicated by gene symbols. Mutations 
are dominant, recessive, or X-linked. 
 
Figure 4 
Generalized photoreceptor diseases affect both photoreceptor cell types, rods and 
cones. They are progressive in the majority of cases and can occur as part of a 
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syndrome (syndromic) or not (non-syndromic). Mutations in various genes, indicated 
by their symbols, are dominant or recessive. X-linked inheritance has not been 
described so far. 
 
Figure 5 
Exudative and erosive vitreoretinopathies (ERVR and EVR). Both, syndromic and 
non-syndromic forms can be caused by dominant, recessive, or X-linked mutations in 
different genes (indicated by gene symbols). 
 
Figure 6 
Clinical symptoms of non-syndromic monogenic retinal and vitreoretinal diseases and 
their causative genes. Clinical diagnoses are indicated by colored circles. Gene 
symbols in the overlapping areas show that mutations in the same gene can lead to 
different phenotypes.  
RP: retinitis pigmentosa; NB: night blindness; LCA: Leber congenital amaurosis; 
CORD/COD: cone-rod and cone dystrophies; CVD: color vision defects; MD: macular 
degeneration; ERVR/EVR: erosive and exudative vitreoretinopathies 
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Table 1: Stationary photoreceptor diseases
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional phenotypes
Calcium-binding protein 4 CABP4 CSNB2B 11q13.1 recessive NM_145200 calcium signalling incomplete CSNB, progressive
Voltage-dependent L-type calcium channel subunit 
alpha-1F
CACNA1F CSNB2A, CORDX3, 
Cav1.4, CSNB2A, 
CSNBX2
Xp11.23 recessive NM_005183 Calcium channel incomplete congenital stationary night blindness
Calcium channel, voltage-dependent, alpha 2/delta 
subunit 4
CACNA2D4 RCD4 12p13.33 recessive NM_172364 ion channel incomplete CSNB, cone dystrophy (ar)
Guanine nucleotide-binding protein G(t) subunit 
alpha-1
GNAT1 - 3p21.31 dominant NM_144499 phototransduction -
Rhodopsin kinase GRK1 GPRK1, RHOK, RK    13q34 recessive NM_002929 phototransduction CSNB with fundus abnormalities
Metabotropic glutamate receptor 6 GRM6 CSNB1B, MGLUR6,  
GPRC1F
5q35 recessive NM_000843 glutamate transport complete CSNB
Nyctalopin NYX CSNB1A Xp11.4 recessive NM_022567 unknown complete CSNB
Rod cGMP-specific 3',5'-cyclic phosphodiesterase 
subunit beta 
PDE6B PDEB, CSNB3, RP40 4p16.13 dominant NM_001145292 phototransduction retinitis pigmentosa
Rhodopsin RHO OPN2, RP4 3q22.1 dominant NM_000539 phototransduction retinitis pigmentosa
Transient receptor potential cation channel subfamily 
M member 1
TRPM1 LTRPC1, MLSN1 15q13.3 recessive NM_002420 ion channel complete CSNB
S-arrestin SAG Arrestin 2q37.1 recessive NM_000541 phototransduction CSNB with fundus abnormalities
Cone dysfunctions (stationary)
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional phenotypes
Cyclic nucleotide-gated channel alpha-3 subunit CNGA3 ACHM2, CNCG3, 
CCNCa, CNG3, 
CCNC1
2q11.2 recessive NM_001298 phototransduction complete or incomplete achromatopsia, typical or 
atypical achromatopsia, rod monochromatism, cone 
rod dystrophy (ar)
Cyclic nucleotide-gated cation channel beta-3 
subunit
CNGB3 ACHM3 8q21.3 recessive NM_019098 phototransduction complete achromatopsia, typical achromatopsia, rod 
monochromatism, macular degeneration
Guanine nucleotide-binding protein G(t) subunit 
alpha-2
GNAT2 ACHM4 1p13.3 recessive NM_005272 phototransduction complete or incomplete achromatopsia, typical or 
atypical achromatopsia, rod monochromatism, 
oligocone trichromacy
Cone-specific phosphodiesterase alpha subunit PDE6C PDEA2 10q23.33 recessive NM_006204 phototransduction complete or incomplete achromatopsia, cone 
dystrophy
Red cone photoreceptor pigment RCP OPN1LW, CBBM, CBP Xq28 recessive NM_020061 phototransduction blue cone monochromatism, X-linked atypical 
achromatopsia, X-linked incomplete achromatopsia
Green cone photoreceptor pigment GCP OPN1MW, CBBM, 
CBD, OPN1MW1
Xq28 recessive NM_001048181 phototransduction blue cone monochromatism, X-linked atypical 
achromatopsia, X-linked incomplete achromatopsia
Blue cone photoreceptor pigment OPN1SW BCP, CBT 7q32.1 dominant NM_001708 phototransduction tritanopia
For references see the corresponding section in this review or the Retnet website. ad: autosomal dominant; ar: autosomal recessive; - : no information 
Congenital stationary night blindness (CSNB)
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Table 2: Retinitis pigmentosa (RP)
Retinitis pigmentosa
Gene names Gene symbol Gene symbol aliases Chromosome Inheritance Reference sequence Potential function Additional phenotype
Carbonic anhydrase 4 CA4 RP17 17q23.2 dominant NM_000717 unknown -
Cone-rod homeobox protein CRX CORD2, CRD, OTX3, 
LCA7
19q13.32 dominant NM_000554 transcription factor cone rod dystrophy (ad), Leber congenital 
amaurosis (ar and ad)
Fascin homolog 2 FSCN2 RP30 17q25.3 dominant NM_012418  cellular structure macular dystrophy (ad)
Guanylate cyclase activator 1B GUCA1B GCAP2 6p21.1 dominant NM_002098 phototransduction macular dystrophy (ad)
Inosine monophosphate dehydrogenase 1 IMPDH1 RP10, LCA11, MPD, 
IMPD1, 
7q32.1 dominant NM_000883 regulation of cell growth Leber congenital amaurosis (ad)
Kelch-like 7 KLHL7 RP42, SBBI26 7p15 dominant NM_001031710 ubiquitin-proteasome protein 
degradation
-
Pim1 associated protein 1 PAP1 RP9, PIM1K 7p14.3 dominant NM_203288 splicing -
Pre-mRNA processing factor 3 homolog PRPF3 RP18, HPRP3, PRP3 1q21.2 dominant NM_004698 splicing -
Pre-mRNA processing factor 31 homolog PRPF31 RP11, PRP31 19q13.42 dominant NM_015629 splicing -
Pre-mRNA processing factor 8 homolog PRPF8 RP13, PRPC8 17p13.3 dominant NM_006445 splicing -
Peripherin 2 PRPH2 RP7, RDS, TSPAN22, 
rd2
6p21.1 dominant NM_000322 photoreceptor outer segment 
structure
macular dystrophy (ad), digenetic forms with 
ROM1, adult vitelliform macular dystrophy 
(ad), pattern dystrophy
Retinol dehydrogenase 12 RDH12 LCA3, LCA13, SDR7C2, 
FLJ30273
14q24.1 dominant NM_152443 phototransduction Leber congenital amaurosis (ar)
Retinal outer segment membrane protein 1 ROM1 RP7, ROSP1, TSPAN23 11q12.3 dominant NM_000327 cellular structure digenic forms with PRPH2
sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4A
SEMA4A RP35, CORD10, SEMAB, 
SemB
1q22 dominant NM_022367 tissue development and 
maintenance
cone rod dystrophy (ad)
Small nuclear ribonucleoprotein 200kDa (U5) SNRNP200 BRR2, HELIC2, 
ASCC3L1, U5-200KD
2q11.2 dominant NM_014014 splicing -
Topoisomerase I binding, arginine/serine-rich TOPORS RP31, LUN, P53BP3 9p21.1 dominant NM_005802 - -
Bestrophin-1 BEST1 VMD2, ARB, BMD, 
TU15B, 
11q12.3 dominant and 
recessive
NM_004183 anion channel autosomal dominant 
vitreoretinochoroidopathy;  Best macular 
dystrophy (BMD) (ad)
Nuclear receptor subfamily 2, group E, 
member 3
NR2E3 ESCS, PNR, RP37, 
MGC49976, rd7, RNR
15q22.32 dominant and 
recessive
NM_016346 transcription factor enhanced S-cone syndrome (ar), Goldmann-
Favre syndrome
Neural retina leucine zipper NRL RP27 14q11.2 dominant and 
recessive
NM_006177 tissue development and 
maintenance
may include clumped pigmentary 
degeneration and preserved blue cone 
function
Retinal G protein coupled receptor RGR RP44 10q23.1 dominant and 
recessive
NM_002921 retinal metabolism choroidal sclerosis (ad)
Rhodopsin RHO RP4, OPN2 3q22.1 dominant and 
recessive
NM_000539 phototransduction CSNB (ad)
Retinitis pigmentosa 1 RP1 ORP1 8q12.1 dominant and 
recessive
NM_006269 tissue development and 
maintenance
-
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ATP-binding cassette, sub-family A member 4 ABCA4 RP19, ABCR, ARMD2, 
CORD3, STGD1
1p22.1 recessive NM_000350 transport Stargardt disease, cone rod dystrophy, 
juvenile and late onset macular 
degeneration, fundus flavimaculatus;  all (ar)
Ceramide kinase-like CERKL RP26 2q31.3 recessive NM_001030311 tissue development and 
maintenance
-
Cyclic nucleotide gated channel alpha 1 CNGA1 CNCG, CNCG1 4p12 recessive NM_000087 phototransduction -
Cyclic nucleotide gated channel beta 1 CNGB1 CNCG2, CNCG3L, 
GAR1, GARP
16q13 recessive NM_001297 phototransduction -
Crumbs homolog 1 CRB1 RP12, LCA8, RP11, 1q31.3 recessive NM_201253 tissue development and 
maintenance
Leber congenital amaurosis (ar), pigmented 
paravenous chorioretinal atrophy (ad), 
retinitis pigmentosa (ar) with para-arteriolar 
preservation of the RPE, sympotoms may 
include Coats-like exudative vasculopathy 
and thick retina with abnormal lamination
Eyes shut homolog EYS RP25, SPAM 6p12 recessive NM_001142800 - -
Lecithin retinol acyltransferase LRAT MGC33103 4q32.1 recessive NM_004744 retinal metabolism Leber congenital amaurosis (ar)
C-mer proto-oncogene tyrosine kinase MERTK RP38, MER, c-mer 2q14.1 recessive NM_006343 transmembrane protein LCA
Phosphodiesterase 6A PDE6A RP43, CGPR-A 5q33.1 recessive NM_000440 phototransduction -
Phosphodiesterase 6B PDE6B RP40, CSNB3 4p16.3 recessive NM_000283 phototransduction CSNB (ad)
Progressive rod-cone degeneration PRCD RP36 17q25.1 recessive NM_001077620 - -
Prominin 1 PROM1 CORD12, CD133, RP41, 
STGD4, AC133, MCDR2, 
PROML1
4p15.32 recessive NM_006017 cellular structure retinitis pigmentosa with macular 
degeneration (ar); Stargardt-like macular 
dystrophy (ad); macular dystrophy (ad); bull's-
eye; cone rod dystrophy (ad)
Retinol binding protein 3 RBP3 IRBP 10q11.22 recessive NM_002900 retinal metabolism -
Retinaldehyde binding protein 1 RLBP1 CRALBP 15q26.1 recessive NM_000326 retinal metabolism rod-cone dystrophy (ar), retinitis punctata 
albescens (ar), Newfoundland rod cone 
dystrophy (ar)
Retinal pigment epithelium-specific protein 
65kDa
RPE65 RP20, LCA2 1p31.2 recessive NM_000329 retinal metabolism Leber congenital amaurosis (ar)
Arrestin, s-antigen SAG RP47, DKFZp686D1084, 
DKFZp686I1383
2q37.1 recessive NM_000541 phototransduction Oguchi disease (ar)
Tubby like protein 1 TULP1 RP14, TUBL1 6p21.31 recessive NM_003322 tissue development and 
maintenance
Leber congenital amaurosis (ar)
Usher syndrome 2A USH2A RP39, USH2, 1q41 recessive NM_206933 cellular structure Usher syndrome, type 2a (ar)
Retinitis pigmentosa 2 RP2 NME10, TBCCD2, 
KIAA0215, DELXp11.3
Xp11.23 recessive NM_006915 tissue development and 
maintenance
-
Retinitis pigmentosa GTPase regulator RPGR RP3, CORDX1, COD1, 
CRD, RP15
Xp11.4 recessive NM_000328 intraflagellar transport cone rod dystrophy (Xl), atrophic macular 
dystrophy (Xl), cone dystrophy (Xl) 
For references see the corresponding section in this review or the Retnet website. ad: autosomal dominant; ar: autosomal recessive; - : no information 
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Table 3: Non-syndromic and syndromic cone and cone rod dystrophies
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Clinical diagnosis
ATP-binding cassette sub-family A member 4 ABCA4 CORD3, FFM, STGD1, 
RP19, ABCR, STGD, 
ARMD2
1p22.1 recessive NM_000350 transport Stargardt disease, retinitis pigmentosa, cone rod 
dystrophy, juvenile and late onset macular degeneration, 
fundus flavimaculatus;  all (ar)
Metalloprotease disintegrin cysteine-rich protein 
9
ADAM9 MDC9, MCMP 8p11.22 recessive  NM_003816 cell/matrix interaction cone rod dystrophy
Aryl-hydrocarbon-interacting protein-like 1 AIPL1 LCA4, AIPL2 17p13.1 dominant NM_014336 transport, protein 
trafficking
cone rod dystrophy, Leber congenital amaurosis (ar)
Voltage-dependent L-type calcium channel 
subunit alpha-1F
CACNA1F CORDX3, CSNB2, 
Cav1.4, CSNB2A, 
CSNBX2
Xp11.23 recessive NM_005183 Calcium channel congenital stationary night blindness, cone rod dystrophy
Voltage-dependent calcium channel subunit 
alpha-2/delta-4
CACNA2D4 RCD4 12p13.33 recessive NM_172364 ion channel cone dystrophy (ar), stationary night blindness (ar)
Cyclic nucleotide-gated cation channel beta-3 
subunit
CNGA3 ACHM2, CNCG3, 
CCNCa, CNG3, CCNC1
2q11.2 recessive NM_001298 phototransduction complete or incomplete achromatopsia, typical or atypical 
achromatopsia, rod monochromatism, cone rod dystrophy 
(ar)
Cellular retinaldehyde-binding protein CRALBP RLBP1 15q26.1 recessive NM_000326 phototransduction retinitis pigmentosa (ar), rod cone dystrophy (ar)
Cone-rod homeobox protein CRX CORD2, CRD, OTX3, 
LCA7
19q13.32 dominant NM_000554 transcription factor cone rod dystrophy (ad), Leber congenital amaurosis (ad, 
ar), retinitis pigmentosa (ad)
Guanylate cyclase activator 1A GUCA1A GCAP1, GUCA, GCAP, 
GUCA1, COD3
6p21.1 dominant NM_000409 phototransduction cone dystrophy (ad) Color and central vision loss (ad)
Retinal guanylate cyclase 2D GUCY2D CORD6, GUC1A4, 
GUC2D, LCA1, LCA, 
retGC, CYGD, RETGC-1, 
ROS-GC1, CORD5
17p13.1 dominant NM_000180 phototransduction Leber congenital amaurosis (ar)
Protein unc-119 homolog A, retinal protein 4 HRG4 UNC119 17q11.2 dominant NM_005148 neurotransmitter release cone rod dystrophy (ad)
Potassium voltage-gated channel subfamily V 
member 2
KCNV2 Kv8.2, RCD3B 9p24.2 recessive NM_133497 ion channel subunit cone dystrophy with supernormal rod electroretinogram
Cone -specific phosphodiesterase alpha subunit PDE6C PDEA2 10q23.33 recessive NM_006204 phototransduction complete or incomplete achromatopsia, cone dystrophy
Retinal cone rhodopsin-sensitive cGMP 3',5'-
cyclic phosphodiesterase subunit gamma
PDE6H RCD3A 12p12.3 recessive NM_006205 phototransduction cone dystrophy with supernormal rod electroretinogram
Membrane-associated phosphatidylinositol 
transfer protein 3
PITPNM3 CORD5, NIR1, RDGBA3 17p13.2 dominant NM_031220 transport cone rod dystrophy
Prominin 1 PROM1 CORD12, CD133, RP41, 
STGD4, AC133, MCDR2, 
PROML1
4p15.32 dominant NM_006017 cellular structure Stargardt disease (ad), retinitis pigmentosa (ar), cone rod 
dystrophy (ad), macular degeneration (ad)
Peripherin-2 PRPH2 RP7, RDS, TSPAN22, rd2 6p21.1 dominant NM_000322 phototransduction retinitis pigmentosa (ad, digenic with ROM1), macular 
degeneration (ad)
Retina and anterior neural fold homeobox 2 RAX2 CORD11, RAXL1, 
ARMD6, QRX
19p13.3 - NM_032753 transcription macular degeneration (isolated cases)
11-cis retinol dehydrogenase 5 RDH5 RDH1 12q13.2 recessive NM_002905 chromophore metabolism late onset cone dystrophy (ar)
Non-syndromic cone and cone rod dystrophies (COD, CORD, progressive)
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Rab3-interacting molecule 1 RIM1 CORD7, RIMS1, 
RAB3IP2, RIM
6q13 dominant NM_014989 neurotransmitter release, 
exocytosis
cone rod dystrophy
Retinitis pigmentosa GTPase regulator RPGR CORDX1, COD1, RP3, 
CRD, RP15
Xp11.4 recessive 
and 
dominant
NM_000328 intraflagellar transport cone dystrophy, cone rod dystrophy, retinitis pigmentosa 
(with deafness and sinorespiratory infections), macular 
degeneration (Xlr, Xld)
Retinitis pigmentosa GTPase regulator 
interacting protein 1
RPGRIP1 CORD13, RPGRIP, LCA6, 
RGI1,RGRIP, RPGRIP1d
14q11.2 recessive NM_020366 interaction with retinitis 
pigmentosa GTPase 
regulator protein
cone rod dystrophy, Leber congenital amaurosis (ar)
Sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4A
SEMA4A CORD10, RP35, SEMAB, 
SemB
1q22 recessive 
and 
dominant
NM_022367 axon guidance cone rod dystrophy (ad, ar), retinitis pigmentosa (ad)
Gene name Gene symbol Gene symbol aliases Chromos. Inheritance Ref.-seq. Potential function Clinical diagnosis
Alstrom syndrome 1 ALMS1 ALSS, DKFZp686A118, 
DKFZp686D1828, 
KIAA0328
2p13 recessive NM_015120.4 component of 
centrosome and cilia
Alstrom syndrome (ar)
Ataxin 7 ATXN7 ADCAII, OPCA3, SCA7 3p14.1 dominant NM_001128149 potential transcription 
factor
spinocerebellar ataxia (ad)
Bardet Biedl syndrome 1 gene BBS1 BBS2L2, FLJ23590, 
MGC51114, MGC126183, 
MGC126184
11q13.1 recessive NM_024649 centrosomal and ciliary 
protein
retinitis pigmentos (ar), Bardet Biedl syndrome 1 (ar)
Cyclin M4 CNNM4 ACDP4, FLJ42791, 
KIAA1592
2q11.2 recessive NM_020184 potential metal 
transporter
Jalli syndrome (ar)
Neurofibromin 1 NF1 FLJ21220, NFNS, VRNF, 
WSS
17q11.2 dominant NM_000267 tumor suppressor neurofibromatosis (ad)
For references see the corresponding section in this review or the Retnet website. ad: autosomal dominant; ar: autosomal recessive; - : no information 
Syndromic cone and cone rod dystrophies (COD, CORD, progressive)
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Table 4a: Non-syndromic and syndromic macular degenerations
Gene name Gene symbol Gene symbol aliases Chromososome Inheritance Ref.-seq. Potential function Additional diagnosis
Retinal-specific ATP-binding cassette 
transporter (ATP-binding cassette sub-family A 
member 4)
ABCA4 CORD3, FFM, STGD1, 
RP19, ABCR, STGD, 
ARMD2
1p22.1 recessive NM_000350 transport Stargardt disease (ar), retinitis pigmentosa (ar), cone rod 
dystrophy (ar), juvenile and late onset macular 
degeneration (ar), fundus flavimaculatus (ar)
Bestrophin 1 BEST1 VMD2, ARB, BMD, 
TU15B, 
11q12.3 dominant NM_004183 anion channel autosomal dominant vitreoretinochoroidopathy;  Best 
macular dystrophy (BMD) (ad)
complement C1q tumor necrosis factor-related 
protein 5 precursor variant 3
C1QTNF5 CTRP5, LORD 11q23.3 dominant NM_015645 small collagen -
Cyclic nucleotide-gated cation channel beta-3 
subunit
CNGB3 ACHM3 8q21.3 recessive NM_019098 phototransduction complete achromatopsia, typical achromatopsia, rod 
monochromatism
Fibulin 3 EFEMP1 FBNL, 3218, DHRD, S1-
5, FBLN3, MTLV
2p16.1 dominant NM_004105 extracellular matrix 
protein
Doyne honeycomb retinal degeneration
Elongation of very long chain fatty acids protein 
4
ELOVL4 STGD3, STGD2 6q14.1 dominant NM_022726 fatty acid metabolism -
Fascin homolog 2 FSCN2 RFSN, RP30 17q25.3 dominant NM_012418  photoreceptor disk 
morphogenesis
mutations in FSCN2 may cause RP 
Guanylate cyclase activator 1B GUCA1B GCAP2 6p21.1 dominant NM_002098 phototransduction retinitis pigmentosa (ad)
Hemicentin 1 HMCN1 ARMD1, FBLN6, FIBL-6, 
FIBL6
1q31.1 dominant NM_031935 extracellular member of 
the immunoglobulin 
superfamily
age-related macular degeneration
Prominin 1 PROM1 CORD12, CD133, RP41, 
STGD4, AC133, MCDR2, 
PROML1
4p15.32 dominant NM_006017 cellular structure Stargardt disease (ad), retinitis pigmentosa (ar), cone rod 
dystrophy (ad)
Peripherin-2 PRPH2 RP7, RDS, TSPAN22, 
rd2
6p21.1 dominant NM_000322 photoreceptor outer 
segment structure
cone dystrophy, cone rod dystrophy, retinitis pigmentosa 
(ad, digenic with ROM1), 
Retinitis pigmentosa GTPase regulator RPGR CORDX1, COD1, RP3, 
CRD, RP15
Xp11.4 recessive 
and dominant
NM_000328 intraflagellar transport cone dystrophy, cone rod dystrophy, retinitis pigmentosa 
(with deafness and sinorespiratory infections), macular 
degeneration (Xlr, Xld)
Retinoschisin RS1 RS, XLRS1 Xp22.13 recessive NM_000330 adhesion molecule? -
Tissue inhibitor of metalloproteinases 3 TIMP3 SFD 22q12.3 dominant NM_000362 ECM remodelling? Sorsby fundus dystrophy (ad)
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Ataxin 7 ATXN7 ADCAII, OPCA3, SCA7 3p14.1 dominant NM_001128149 potential transcription 
factor
spinocerebellar ataxia (ad)
Bardet Biedl syndrome 1 gene BBS1 BBS2L2, FLJ23590, 
MGC51114, MGC126183, 
MGC126184
11q13.1 recessive NM_024649 centrosomal and ciliary 
protein
retinitis pigmentos (ar), Bardet Biedl syndrome 1 (ar)
Peroxisomal biogenesis factor 1 PEX1 IRD 7q21.2 recessive NM_000466 peroxisomal protein 
import
infantile form of phytanic acid storage disease
Peroxisomal biogenesis factor 26 PEX26 PEX26M1T, Pex26pM1T 22q11.21 recessive NM_017929 peroxisomal protein 
import
infantile form of phytanic acid storage disease
Peroxisomal membrane protein 3 PXMP3 PEX2, PMP35, PAF-1 8q21.11 recessive NM_000318 peroxisome biogenesis infantile form of phytanic acid storage disease
For references see the corresponding section in this review or the Retnet website. ad: autosomal dominant; ar: autosomal recessive; - : no information 
Non-syndromic macular degenerations (MD), ARMD not included
Syndromic macular degenerations (MD)
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AMD associated genes
Gene name Gene symbol Gene symbol aliases Chromosome Ref.-Seq. Potential function Additional diagnosis
ATP-binding cassette sub-family A member 4 ABCA4 ARMD2, ABCR, CORD3, FFM, 
RP19, STGD, STGD1
1p22.1 NM_000350 transport Stargardt disease, retinitis pigmentosa, cone rod 
dystrophy, juvenile and late onset macular 
degeneration, fundus flavimaculatus;  all (ar)
Apolipoprotein E APOE AD2, LDLCQ5, LPG, MGC1571 19q13.2 NM_000041 catabolism of triglyceride-rich lipoprotein familial dysbetalipoproteinemia (ad and ar), or type III 
hyperlipoproteinemia (HLP III) (ar and ad), end-stage 
renal disease (ESRD)(ad), Susceptibility to Alzheimer's 
disease
Age-related maculopathy susceptibility 2 ARMS2 ARMD8 10q26.13 NM_001099667 mitochondrial outer membrane protein -
Complement component 2 C2 DADB-122G4.1, CO2, 
DKFZp779M0311
6p21.3 NM_000063 classical pathway of complement system -
Complement component 3 C3 ARMD9, ASP, CPAMD1 19p13.3 NM_001735 activation of complement system Susceptibility to bacterial infection
Complement factor B CFB DADB-122G4.5, BF, BFD, CFAB, 
FB, FBI12, GBG, H2-Bf, PBF2
6p21.3 NM_001710 immune system; complement and coagulation 
cascades 
-
Complement factor H CFH ARMD4, ARMS1, CFHL3, HUS, 
MGC88246
1q32 NM_000186 immune system; complement and coagulation 
cascades 
atypical hemolytic uremic syndrome
Cystatin C CST3 ARMD11, MGC117328 20p11.21 NM_000099 extracellular inhibitor of cysteine proteases amyloid angiopathy AMD
Excision repair cross-complementing rodent repair 
deficiency
ERCC6 ARMD5, CKN2, COFS, COFS1, 
CSB, RAD26
10q11.23 NM_000124 DNA repair Cockayne syndrome type B (ar)
Fibulin 5 FBLN5 ARMD3, DANCE, EVEC, FIBL-5, 
FLJ90059, UP50
14q32.1 NM_006329 vascular development and remodeling autosomal dominant cutis laxa, cutis laxa type I (ar)
Hemicentin 1 HMCN1 ARMD1,FBLN6, FIBL-6, FIBL6 1q31.1 NM_031935 extracellular member of the immunoglobulin 
superfamily
macular deheneration (ad)
HtrA serine peptidase 1 HTRA1 ARMD7, HtrA, L56, ORF480, 
PRSS11
10q26.3 NM_002775 regulation of  availability of insulin-like growth 
factors; regulator of cell growth 
-
Interleukin 8 IL-8 CXCL8, GCP-1, GCP1, LECT, 
LUCT, LYNAP, MDNCF, MONAP, 
NAF, NAP-1, NAP1
4q13-q21 NM_000634 mediators of  inflammatory response; 
chemoattractant; angiogenic factor
-
Pleckstrin homology domain containing, family A PLEKHA1 TAPP1 10q26.13 NM_021622 - -
Paraoxonase 1 PON1 ESA, PON 7q21.3 NM_000446 arylesterase risk factor in coronary artery disease and amylotrophic 
lateral sclerosis (ALS)
retina and anterior neural fold homeobox 2 RAX2 ARMD6, CORD11, QRX, RAXL1 19p13.3 NM_032753 transcription cone-rod dystrophy type 11
Serpin peptidase inhibitor, clade G (C1 inhibitor), 
member 1
SERPING1 C1IN, C1INH, C1NH, HAE1, 
HAE2
11q12 NM_000062 regulation of the complement cascade hereditary angioneurotic oedema (HANE) (ar)
Toll-like receptor 3 TLR3 CD283 4q35 NM_003265 pathogen recognition and activation of innate 
immunity
-
Toll-like receptor 4 TLR4 ARMD10, CD284, TOLL, hToll 9q32 NM_138554 innate immune system  lipopolysaccharide responsiveness
Vascular endothelial growth factor A VEGFA RP1-261G23.1, MGC70609, 
MVCD1, VEGF, VEGF-A, VPF
6p12  NM_001025366 vascular permeability, angiogenesis, 
vasculogenesis and endothelial cell growth,  cell 
migration, apoptosis
 diabetic retinopathy
For references see the corresponding section in this review or the Retnet website. ad: autosomal dominant; ar: autosomal recessive; - : no information 
Table 4b: Age-related macular degeneration
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Table 5: Non-syndromic and syndromic generalized photoreceptor diseases
Leber congenital amaurosis (LCAs)
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Aryl-hydrocarbon-interacting protein-like 1 AIPL1 LCA4, AIPL2 17p13.1 recessive NM_014336 protein-protein interaction cone rod dystrophy (ad)
Centrosomal protein 290 CEP290 LCA10, SLSN6, MKS4, 
JBTS5, BBS14, NPHP6
12q21.32 recessive NM_025114 centrosomal and ciliary 
protein
Senior Loken syndrome type 6 (ar), Meckel syndrome 
type 4 (ar), Joubert syndrome type 5 (ar), Bardet Biedl 
syndrome type 14 (ar)
Crumbs homolog 1 CRB1 LCA8, RP11, RP12 1q31.3 recessive NM_201253 tissue development and 
maintenance
severe retinitis pigmentosa (ar), pigmented 
paravenous chorioretinal atrophy (ad), 
Cone-rod homeobox protein CRX LCA7, CORD2, CRD, 
OTX3
19q13.32 recessive 
and rarely 
dominant
NM_000554 transcription factor cone rod dystrophy (ad), retinitis pigmentosa (ad)
Retinal guanylate cyclase 2D GUCY2D LCA1, CORD6, GUC1A4, 
GUC2D, LCA, retGC, 
CYGD, RETGC-1, ROS-
GC1, CORD5
17p13.1 recessive NM_000180 phototransduction cone rod dystrophy (ad)
Inosine monophosphate dehydrogenase 1 IMPDH1 LCA11, IMPD, IMPD1, 
RP10
7q32.1 recessive 
and rarely 
dominant
NM_000883 regulation of cell growth retinitis pigmentosa (ad)
Leber congenital amaurosis 5 LCA5 LCA5, C6ORF152, 
Lebercillin
6q14.1 recessive NM_181714 centrosomal protein with 
ciliary function
-
Lecithin retinol acyltransferase LRAT MGC33103 4q32.1 recessive NM_004744 retinal metabolism early-onset severe retinal dystrophy (ar)
C-mer proto-oncogene tyrosine kinase MERTK MER, RP38, c-mer 2q14.1 recessive NM_006343 transmembrane protein retinitis pigmentosa (ar)
Retinal degeneration 3 RD3 LCA12, C1ORF36 1q32.3 recessive NM_183059 transcription and splicing -
Retinol dehydrogenase 12 RDH12 FLJ30273, LCA3, LCA13, 
SDR7C2
14q24.1 recessive NM_152443 phototransduction retinitis pigmentosa (ad)
Retinal pigment epithelium-specific protein 
65kDa 
RPE65 LCA2, RP20, 1p31.2 recessive NM_000329 visual cycle retinitis pigmentosa (ar)
Retinitis pigmentosa GTPase regulator 
interacting protein 1
RPGRIP1 LCA6, CORD13, RGI1, 
RGRIP, RPGRIP, 
RPGRIP1d
14q11.2 recessive NM_020366 interaction with retinitis 
pigmentosa GTPase 
regulator protein
congenital blindness, cone rod dystrophy (ar)
Spermatogenesis associated 7 SPATA7 HSD-3.1, HSD3, LCA3 14q31.3 recessive NM_018418 - juvenile retinitis pigmentosa (ar)
Tubby like protein 1 TULP1 RP14, TUBL1 6p21.31 recessive NM_003322 tissue development and 
maintenance
retinitis pigmentosa (ar)
Gyrate atrophy
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Ornithine aminotransferase OAT HOGA 10q26.13 recessive NM_000274 neurotransmitter metabolism -
Choroideremia
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Choroideremia protein CHM TCD, REP-1 Xq21.2 recessive NM_000390 protein prenylation -
Alagille syndrome
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Jagged1 JAG1 AGS 20p12.2 dominant NM_000214 development, notch signalling -
Notch 2 receptor NOTCH2 hN2, AGS2 1p12 dominant NM_024408 development, notch signalling -
Neuronal ceroid lipofuscinosis (CLN), Batten disease
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Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Battenin, Batten disease protein BTS CLN3, JNCL 16p12.1 recessive NM_000086 lysosomal protein -
Ceroid-lipofuscinosis neuronal protein 5 CLN5 - 13q22.3 recessive NM_006493 unknown -
Ceroid-lipofuscinosis neuronal protein 6 CLN6 - 15q23 recessive NM_017882 unknown -
Ceroid-lipofuscinosis neuronal protein 7 CLN7 MFSD8 4q28.2 recessive NM_152778 lysosomal transporter -
Ceroid-lipofuscinosis neuronal protein 8 CLN8 - 8p23 recessive NM_018941 ER / Glogi protein -
Cathepsin D CTSD CLN10, CPSD 11p15.5 recessive NM_001909 intracellular protease -
Palmitoyl-protein hydrolase 1 PPT1 CLN1, PPT 1p34.2 recessive NM_000310 lysosomal degradation macular degeneration, retinal degeneration
Tripeptidyl-peptidase 1 TPP1 CLN2 11p15.4 recessive NM_000391 lysosomal protease -
Refsum disease
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Phytanoyl-CoA 2-hydroxylase PAHX PHYH, PHYH1 10p13 recessive NM_001037537 peroxisomal fatty acid 
oxidation
-
Peroxisome biogenesis factor 1 PEX1 IRD 7q21.2 recessive NM_000466 peroxisomal protein import -
Peroxisome assembly protein 26 PEX26 FLJ20695, PEX26M1T, 
Pex26pM1T
22q11.21 recessive NM_017929 peroxisomal protein import -
Peroxisomal targeting signal 2 receptor PEX7 PTS2R 6q23.3 recessive NM_000288 peroxisome biogenesis -
peroxisomal membrane protein 3 PXMP3 PEX2,  PMP35, PAF-1 8q21.11 recessive NM_000318 peroxisome biogenesis infantile form of phytanic acid storage disease
Joubert syndrome
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Abelson helper integration1 AHL1 JBTS3; ORF1; AHI-1 6q23.3 recessive NM_017651          - -
ADP-ribosylation factor-like 13B ARL13B JBTS8, ARL2L1 3q11.2 recessive NM_182896 ciliary function -
Coiled-coil and C2 domain containing 2A CC2D2A JBTS9, KIAA1345, MKS6 4p15.33 recessive NM_001080522 interaction with protein 
CEP290
mental retardation with retinitis pigmentosa (ar)
Centrosomal protein 290 CEP290 LCA10, SLSN6, MKS4, 
JBTS5, BBS14, NPHP6
12q21.32 recessive NM_025114 centrosomal and ciliary 
protein
Senior Loken syndrome type 6 (ar), Meckel syndrome 
type 4 (ar), Bardet Biedl syndrome type 14 (ar), Leber 
congenital amaurosis type 10 (ar)
Nephronophthisis 1 NPHP1 JBTS4, SLSN1 2q13 recessive NM_000272 control of cell division, cell-
cell and cell-matrix adhesion 
signaling, complex in actin- 
and microtubule-based 
structures
-
Oral-facial-digital syndrome 1 OFD1 JBTS10 Xp22 recessive NM_003611 interacts with LCA5-encoded 
lebercilin
-
RPGR-interacting protein 1-like protein RPGRIP1L JBTS7, KIAA1005, MKS5, 
NPHP8
16q12.2 recessive NM_015272 localization to centrosome 
and primary cilia
Meckel syndrome (ar)
Transmembrane protein 67 TMEM67 JBTS6, MKS3, 8q24 recessive NM_153704 ciliary function Meckel syndrome (ar)
Transmembrane protein 216 TMEM216 JBTS2 11q12.2 recessive NM_016499 -
Senior Loken syndrome
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Centrosomal protein 290 CEP290 LCA10, SLSN6, MKS4, 
JBTS5, BBS14, NPHP6
12q21.32 recessive NM_025114 centrosomal and ciliary 
protein
Joubert syndrome 5 (ar), Meckel syndrome type 4 (ar), 
Bardet Biedl syndrome type 14 (ar), Leber congenital 
amaurosis type 10 (ar)
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Nephrocystin 1 NPHP1 SLSN1, JBTS4 2q13 recessive NM_000272 cell division, adhesion Nephronophthisis (ar), Joubert syndrome type 4 (ar)
Nephrocystin 2 NPHP2 INVS, inversin 9q31 recessive NM_183245 cell cycle Nephronophthisis (ar)
Nephrocystin 3 NPHP3 SLSN3 3q22.1 recessive NM_153240 unknown Nephronophthisis (ar)
Nephrocystin 4, Nephroretinin NPHP4 SLSN4 1p36.31 recessive NM_015102 unknown Nephronophthisis (ar)
Nephrocystin 5 NPHP5 SLSN5, IQCB1 3q13.33 recessive NM_001023570 unknown Nephronophthisis (ar)
For references see the corresponding section in this review or the Retnet website. ad: autosomal dominant; ar: autosomal recessive; - : no information available
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Table 6: Exudative and erosive vitreoretinopathies
Non-syndromic exudative vitreoretinopathies (EVR)
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Frizzled-4 FZD4 EVR1, CD344 11q14.2 dominant NM_012193 Wnt signalling -
Low-density lipoprotein receptor-related protein 5 LRP5 EVR4, OPPG, OPS, 
LR3, BMND1
11q13.2 recessive NM_002335 Wnt signalling Osteoporosis pseudoglioma syndrome (OPPG, ar), 
osteoporosis (ad), bone mineral density quantitative 
trait locus 
Norrin NDP EVR2 Xp11.3 X-linked 
recessive
NM_000266 Ligand of FZD4 and 
LRP5
Norrie disease pseudoglioma (Xlr), retinopathy of 
prematurity (ROP)
Tetraspanin 12 TSPAN12 TM4SF12, NET-2 7q31.31 dominant NM_012338 Norrin-coreceptor -
Non-syndromic erosive vitreoretinopathies (ERVR)
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Bestrophin 1 BEST1 VMD2, ARB, BMD, 
TU15B, 
11q12.3 dominant NM_004183 anion channel autosomal dominant vitreoretinochoroidopathy;  Best 
macular dystrophy (BMD) (ad)
Potassium inwardly-rectifying channel KCNJ13 KIR1.4, KIR7.1, 
MGC33328, SVD
2q37 dominant NM_002242 potassium channels snowflake vitreoretinal degeneration (SVD) (ad)
Nuclear receptor subfamily 2, group E, member 3 NR2E3 ESCS, MGC49976, 
PNR, RNR, RP37, rd7
15q22.32 dominant NM_016346 transcription factor enhanced S cone syndrome (ESCS) (ad and ar); 
retinitis pigmentosa type 37 (ad); Goldmann-Favre 
Syndrome
Versican VCAN CSPG2, ERVR, PG-M, 
WGN, WGN1
5q14.3 dominant NM_004385 hyaluronic acid binding, 
extracellular matrix
Wagner syndrome 1, ERVR (ad)
Syndromic Vitreoretinopathies
Stickler syndrome
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Collagen, type II, alpha 1 COL2A1 ANFH, AOM, 
COL11A3, 
MGC131516, SEDC
12q13.11 dominant NM_001844 extracellular matrix achondrogenesis, chondrodysplasia, early onset 
familial osteoarthritis, SED congenita, Langer-Saldino 
achondrogenesis, Kniest dysplasia, and 
spondyloepimetaphyseal dysplasia Strudwick type (ad 
and ar)
Collagen, type XI, alpha 1 COL11A1 CO11A1, COLL6, STL2 1p21 dominant NM_001854 extracellular matrix Marshall syndrome (ad)
Collagen, type XI, alpha 2 COL11A2 DADB-100D22.2, 
DFNA13, DFNB53, 
HKE5, PARP, STL3
6p21.3 dominant NM_080680 extracellular matrix  otospondylomega-epiphyseal dysplasia (OSMED 
syndrome) (ad), Weissenbacher-Zweymuller 
syndrome (ar), non-syndromic sensorineural type 13 
deafness (DFNA13) (ad), non-syndromic 
sensorineural type 53 deafness (DFNB53) (ar)
Collagen, type IX, alpha 1 COL9A1 RP1-138F4.2, 
DJ149L1.1.2, EDM6, 
FLJ40263, MED
6q12-q14 recessive  NM_001851 structural association with 
collagen type II and XI
-
Norrie disease pseudoglioma
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Norrin NDP EVR2 Xp11.3 X-linked 
recessive
NM_000266 Ligand of FZD4 and 
LRP5
Norrie disease pseudoglioma (Xlr), retinopathy of 
prematurity (ROP)
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Osteoporosis pseudoglioma syndrome
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Low-density lipoprotein receptor-related protein 5 LRP5 EVR4, OPPG, OPS, 
LR3, BMND1
11q13.2 recessive NM_002335 Wnt signalling Osteoporosis pseudoglioma syndrome (OPPG, ar), 
osteoporosis (ad), bone mineral density quantitative 
trait locus 
For references see the corresponding section in this review or the Retnet website. ad: autosomal dominant; ar: autosomal recessive; - : no information available
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Table 8: Syndromic, rod dominated retinal degenerations
Bardet Biedl syndrome
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function additional phenotype
Bardet Biedl Syndrome gene 1 BBS1 BBS2L2, FLJ23590, 
MGC51114, 
MGC126183, 
MGC126184
11q13.1 recessive NM_024649 centrosomal and ciliary 
protein
retinitis pigmentosa (ar), macular degeneration (ar), 
cone rod dystrophy (ar)
Bardet Biedl Syndrome gene 2 BBS2 MGC20703 16q13 recessive NM_031885 cilia formation and function -
Bardet Biedl Syndrome gene 3 BBS3 ARL6 3q11.2 recessive NM_032146 ciliary transport -
Bardet Biedl Syndrome gene 4 BBS4 - 15q24.1 recessive NM_033028 basal bodies and cetriolar 
statelites
-
Bardet Biedl Syndrome gene 5 BBS5 - 2q31.1 recessive NM_152384 basal bodies -
Bardet Biedl Syndrome gene 6 BBS6 MKKS, HMCS, KMS, 
MKS
20p12.2 recessive NM_018848 protein folding McKusick-Kaufmann syndrome (ar)
Bardet Biedl Syndrome gene 7 BBS7 BBS2L1, FLJ10715 4q27 recessive NM_176824 cilia formation and function -
Bardet Biedl Syndrome gene 8 BBS8 TTC8 14q31.3 recessive NM_144596 basal bodies and 
centrosomes
-
Bardet Biedl Syndrome gene 9 BBS9 PTHB1, MGC118917 7p14.3 recessive NM_198428 cilia formation and function -
Bardet Biedl Syndrome gene 10 BBS10 C12orf58, FLJ23560 12q21.2 recessive NM_024685 protein folding -
Bardet Biedl Syndrome gene 11 BBS11 TRIM32, HT2A, TATIP, 
LGMD2H
9q33.1 recessive NM_012210 proteasome degradation -
Bardet Biedl Syndrome gene 12 BBS12 C4orf24, FLJ35630, 
FLJ41559
4q27 recessive NM_152618 protein folding -
Bardet Biedl Syndrome gene 14 CEP290 BBS14, LCA10, 
SLSN6, MKS4, JBTS5, 
NPHP6
12q21.32 recessive NM_025114 centrosomal and ciliary 
protein
Senior Loken syndrome (ar), Meckel syndrome (ar), 
Joubert syndrome (ar), LCA (ar)
Joubert syndrome
Gene name Gene symbol Gene symbol aliases Chromosome Inheritance Ref.-seq. Potential function Additional diagnosis
Abelson helper integration1 AHL1 JBTS3; ORF1; AHI-1 6q23.3 recessive NM_017651           - -
ADP-ribosylation factor-like 13B ARL13B JBTS8, ARL2L1 3q11.2 recessive NM_182896 ciliary function -
Coiled-coil and C2 domain containing 2A CC2D2A JBTS9, KIAA1345, 
MKS6
4p15.33 recessive NM_001080522 interaction with protein 
CEP290
mental retardation with retinitis pigmentosa (ar)
Centrosomal protein 290 CEP290 JBTS5, BBS14, LCA10, 
MKS4, NPHP6, SLSN6
12q21.32 recessive NM_025114 localized to  centrosome and 
cilia, interaction with protein 
CC2D2A
Senior Loken syndrome type 6 (ar), Leber congenital 
amaurosis (LCA10, ar), Meckel syndrome type 4 
(ar),Bardet Biedl syndrome 14 (ar)
Nephronophthisis 1 NPHP1 JBTS4, SLSN1 2q13 recessive NM_000272 control of cell division, cell-
cell and cell-matrix adhesion 
signaling, complex in actin- 
and microtubule-based 
structures
-
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Oral-facial-digital syndrome 1 OFD1 JBTS10 Xp22 recessive NM_003611 interacts with LCA5-encoded 
lebercilin
-
RPGR-interacting protein 1-like protein RPGRIP1L JBTS7, KIAA1005, 
MKS5, NPHP8
16q12.2 recessive NM_015272 localization to centrosome 
and primary cilia
Meckel syndrome (ar)
Transmembrane protein 67 TMEM67 JBTS6, MKS3, 8q24 recessive NM_153704 ciliary function Meckel syndrome (ar)
Transmembrane protein 216 TMEM216 HSPC244 11q12.2 recessive NM_016499 ciliary function -
Gene name Gene symbol Gene symbol aliases Chromososome Inheritance Ref.-seq. Potential function Additional diagnosis
Axonemal dynein heavy chain 11 DNAH11 DPL11, DNAHC11, 
2942, DNAHBL, 
DNHBL, CILD7
7p15.3 recessive NM_003777 motor ATPase -
Axonemal dynein heavy chain 5 DNAH5 HL1, KTGNR, 2950, 
DNAHC5, CILD3, PCD
5p15.2 recessive NM_001369 -
Axonemal dynein intermediate chain 1 DNAI1 CILD1, PCD 9p13.3 recessive NM_012144 -
Axonemal dynein intermediate chain 2 DNAI2 CILD9 17q25.1 recessive NM_023036 -
Kintoun KTU C14orf104, 20188, 
FLJ10563
14q22.1 recessive NM_018139 -
Thioredoxin domain-containing protein 3 TXNDC3 CILD6, NME8, SPTRX2 7p14.1 recessive NM_016616 protein disulfide reductase -
Gene name Gene symbol Gene symbol aliases Chromososome Inheritance Ref.-seq. Potential function Additional diagnosis
Phytanoyl-CoA 2-hydroxylase PAHX PHYH, PHYH1 10p13 recessive NM_001037537 peroxisomal fatty acid 
oxidation
adult form
Peroxisomal biogenesis factor 1 PEX1 IRD 7q21.2 recessive NM_000466 peroxisomal protein import infantile form of phytanic acid storage disease
Peroxisomal targeting signal 2 receptor PEX7 PTS2R 6q23.3 recessive NM_000288 peroxisome biogenesis adult form
peroxisomal biogenesis factor 26 PEX26 PEX26M1T, 
Pex26pM1T
22q11.21 recessive NM_017929 peroxisomal protein import infantile form of phytanic acid storage disease
Peroxisome assembly factor 1 (PAF-1), 
Peroxin-2
PXMP3 PEX2, PMP35, PAF-1 8q21.11 recessive NM_000318 peroxisome biogenesis infantile form of phytanic acid storage disease
Senior Loken syndrome
Gene name Gene symbol Gene symbol aliases Chromososome Inheritance Ref.-seq. Potential function Additional diagnosis
Centrosomal protein 290 CEP290 SLSN6, MKS4, JBTS5, 
NPHP6, BBS14, LCA10
12q21.32 recessive NM_025114 centrosomal and ciliary 
protein
Leber congenital amaurosis (LCA10, ar), Meckel 
syndrome type 4 (ar), Joubert syndrome 5 (ar), Bardet 
Biedl syndrome 14 (ar)
Nephrocystin 1 NPHP1 SLSN1, JBTS4 2q13 recessive NM_000272 cell division, adhesion Nephronophthisis (ar), Joubert syndrome type 4 (ar)
Nephrocystin 2 NPHP2 INVS 9q31 recessive NM_183245 cell cycle Nephronophthisis (ar)
Nephrocystin 3 NPHP3 SLSN3 3q22.1 recessive NM_153240 - Nephronophthisis (ar)
Nephrocystin 4, Nephroretinin NPHP4 SLSN4 1p36.31 recessive NM_015102 - Nephronophthisis (ar)
Nephrocystin 5 NPHP5 SLSN5, IQCB1 3q13.33 recessive NM_001023570 - Nephronophthisis (ar)
Refsum disease
Primary ciliary dyskinesias (PCD)
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Usher syndrome (USH)
Gene name Gene symbol Gene symbol aliases Chromososome Inheritance Ref.-seq. Potential function Additional diagnosis
Clarin-1 CLRN1 USH3A 3q25.1 recessive NM_052995 ribbon synapse? -
Clarin-3 CLRN3 USH3AL1, TMEM12 10q26.2 recessive NM_152311 - -
Deafness, autosomal recessive 31 DFNB31 USH2D, CIP98, WHRN, 
DFNB31
9q32 recessive NM_001083885 - deafness (ar)
G-protein coupled receptor 98 GPR98 USH2C, FEB4, MASS1, 
VLGR1b
5q14.3 recessive NM_032119 - -
Myosin-VIIa MYO7A USH1B, NSRD2, 
DFNA11, DFNB2
11q13.5 recessive NM_000260 vesicle trafficking, transport deafness (ar)
Protocadherin-15 PCDH15 USH1F, DFNB23 10q21.1 recessive NM_001142764 cell adhesion deafness (ar), digenic Usher syndrome with CDH23
Usher syndrome type-1G protein SANS USH1G, ANKS4A 17q25.1 recessive NM_173477 scaffold protein -
Harmonin USH1C AIE-75, PDZ73, PDZ-
73, DFNB18
11p15.1 recessive NM_005709 - deafness (ar)
Cadherin-23 Precursor, Otocadherin USH1D CDH23, DFNB12 10q22.1 recessive NM_052836 cell adhesion deafness (ar), digenic Usher syndrome with PCDH15
Usher syndrome 2A USH2A USH2, RP39 1q41 recessive NM_206933 cellular structure retinitis pigmentosa (ar)
For references see the corresponding section in this review or the Retnet website. ad: autosomal dominant; ar: autosomal recessive; - : no information available
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